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ABSTRACT 
 Cows in early lactation enter into a state of negative energy balance due to 
their high energetic demands and inability to consume adequate amounts of dietary 
energy.  During this period, the transition cow is at increased risk of experiencing 
health or metabolic disorders, which can limit production and ultimately farm 
profitability.  The broad based objective of this thesis was to examine the potential 
beneficial effects of supplementing conjugated linoleic acid (CLA) or organic zinc 
(OZ) during the periparturient period. Feeding CLA reduced milk fat content in early 
lactation, but did not improve other aspects of milk production, health indices or 
reproductive parameters.  Supplementing OZ increased colostrum immunoglobulin 
G (IgG) concentration and milk urea nitrogen (MUN) in multiparous cows.  However, 
feeding increasing OZ did not affect milk yield, feed efficiency or plasma 
bioenergetics variables. 
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CHAPTER 1 
LITERATURE REVIEW 
THE TRANSITION PERIOD 
 During the transition period, the lactating dairy cow experiences a reduction in 
feed intake, parturition, initiates lactogenesis, and is subject to multiple pen 
relocations (Grummer, 1995). Many diseases associated with the transition period 
are a manifestation of the cow’s inability to effectively partition nutrients in 
accordance with new metabolic demands of high milk production.  In order for the 
cow to successfully transition through physiological states she must undergo 
substantial and coordinated metabolic shifts (Bauman and Currie, 1980; Bauman et 
al., 1985; Goff and Horst, 1997; Drackley, 1999).  If these shifts are not effectively 
managed and coordinated the risk of metabolic disease increases.  Transition period 
disorders cause economic losses to the dairy industry, are an animal welfare 
concern, and compromise farm sustainability (Mulligan et al., 2008). Combining 
incidence rates for common transition period health problems (dystocia, metritis, 
ketosis, fatty liver, etc.), indicates approximately 50% of all cows experience at least 
one of these disorders during the periparturient period (Ferguson, 2001).  Transition 
period health disorders decrease the likelihood of a profitable lactation, and this is 
mediated primarily by reduced production and compounded by veterinary costs 
(Drackley, 1999).  For example, a 2 kg loss in production from a cow’s peak lactation 
could ultimately reduce revenue by 200-300 kg worth of milk throughout the entire 
lactation (Wallace et al., 1996).  
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 Nutrient Partitioning During the Transition Period 
  From 250 days of gestation through four days post-partum, the net energy 
demanded by the gravid uterus and mammary gland will increase up to five fold for 
fatty acids, three fold for glucose and will double amino acid requirements (Bell, 
1995).  Upon parturition, genetically superior cows will produce more milk through 
catabolism of body tissue, and consequently have greater voluntary feed intake 
compared to inferior, lower yielding cows (Bryant and Trigg, 1981; Davey et al., 
1983). Proposed by Bauman and Currie (1980), this period of nutrient partitioning is 
being regulated by homeostatic and homeorhetic physiological mechanisms.  
Homeostasis is defined as the coordination of minute-by-minute conditions to 
preserve vital function.  Homeorhesis modifies and coordinates homeostatic 
signaling to partition nutrients to support a dominant physiological state (i.e. 
lactation).   
 Beginning three weeks prior to parturition, there is a gradual decrease in dry 
matter intake (DMI), which is accentuated during the final week prepartum.  During 
this time frame, a 30% decline in DMI is typical for heifers and mature cows 
(Coopock et al., 1972; Hernandez-Urdaneta et al., 1976; Johnson and Otterby, 
1981).   Due to inadequate DMI and subsequent tissue mobilization, the transition 
cow is prone to body weight (BW) loss and a decrease in body condition score 
(BCS) (NRC, 2001).  Body weight change serves as gross predictor of energetic 
status; however, in early lactation body tissues are catabolized while DMI is 
simultaneously increasing, thus making it difficult to measure tissue mobilization 
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solely on BW changes (Moore et al., 2005a).  Consequently, measuring change in 
BCS is probably a more practical physical appraisal of tissue mobilization or 
energetic status in transitioning dairy cows (NRC, 2001; Moore et al., 2005a).   
 As a result of the cow’s increasing energetic demands coupled with 
inadequate nutrient intake, body reserves are mobilized (Bauman and Currie, 1980; 
Drackley et al., 1991).  Due to negative energy balance (NEBAL), adipose 
triacylglycerols (TAG) mobilization increases and this causes blood concentrations 
of nonesterified fatty acid (NEFA) to increase (Figure 1.1). Excessive mobilization of 
TAG can lead to an increased NEFA uptake by the liver. Fatty liver develops from a 
greater rate of NEFA esterification than fatty acid oxidation and results from 
insufficient secretion of hepatic very low density lipoprotein (VLDL; Litherland et al., 
2011).  Nonesterified fatty acids can be completely oxidized to carbon dioxide (CO2) 
or can be partially oxidized to ketone bodies (Nafikov et al., 2006).  An excessive 
buildup of ketones in blood can lead to periparturient ketosis which is associated 
with increasing concentration of liver lipids and decreasing hepatic glycogen content 
(Drackley et al., 1992).  Increased adipose mobilization occurs even if nutrient intake 
does not decrease as elevated plasma NEFA (liberated from adipose triglyceride 
lipolysis) concentrations persisted despite efforts by Bertics and colleagues (1992) to 
force feed cows until calving, at levels commensurate to average consumption via 
rumen fistula.  In addition, mastectomized cows have increased NEFA during the 
transition period (Goff et al., 2002) and this indicates that adipose mobilization is not 
totally dependent upon lactogenesis or galactopoiesis.     
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Endocrine Changes   
 As the transition cow progresses from late gestation to early lactation, 
circulating plasma concentrations of insulin (IN) decrease while plasma 
concentrations of growth hormone increase (Kuntz et al., 1985).  In addition, adipose 
and lean tissues become moderately IN resistant during this period (Petterson et al., 
1993; Bell, 1995).  Insulin serves as a potent signal for regulating adipocyte NEFA 
uptake and TAG storage.  As described by Grummer (1995), the decrease in plasma 
IN during the transition period initiates a series of homeorhetic shifts in nutrient  
 
Figure 1.1: Fates of mobilized fat from adipose tissue in the lactating dairy cow.  
Adapted from Drackley (1999). 
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partitioning.  Reduced IN action also affects post-absorptive carbohydrate 
metabolism (Table 1.1) resulting in a reduction of glucose uptake by muscle and 
adipose tissues (Bauman and Currie, 1980).   
 
Table 1.1: List of metabolic adaptations associated with the transition period in 
ruminants. 
Physiological Function Metabolic Change Tissues Involved 
Milk Synthesis Increased use of 
nutrients 
Mammary gland 
Lipid Metabolism Increased lipolysis 
Decreased lipogenesis 
Adipose tissue 
Glucose Metabolism Increased 
gluconeogenesis 
Increased glycogenolysis 
Decreased use of 
glucose and increased 
use of lipid as energy 
source 
Liver 
 
Whole body 
Protein Metabolism Mobilization of protein 
reserves 
Muscle and other body 
tissue 
Mineral Metabolism Increased absorption and 
mobilization of calcium 
Kidney, liver, gut and 
bone 
      Adapted from Bauman and Currie, 1980. 
 
Energy Balance 
 Energy balance (EBAL) is the calculated difference between energy input 
(dietary intake) and output (energy required for maintenance, immune function, 
growth and milk synthesis).  Methods to directly measure EBAL, such as calorimetry, 
are not practical so other estimation methods have been derived to calculate EBAL 
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[NRC, 2001; EBAL = net energy intake – (net energy of maintenance + net energy of 
lactation)].  Estimation validity is dependent upon how accurately the energy for 
consumed feed, milk produced and energy required for maintenance are calculated 
(Vicini et al., 2002).   
Net energy intake is calculated by multiplying daily DMI by the net energy 
content of the diet.  Determining intake for a pen is relatively simple in a TMR-based 
system, determining intakes in a pasture-based system is much more difficult.  The 
most accurate way to measure individual cow’s DMI is to feed cows using tie-stall 
facilities or a Calan feeding system; however, these approaches are impractical on 
large dairy herds.   
Energy required for maintenance is based on an equation (net energy for 
maintenance = 0.08 x BW0.75).  This equation has remained unchanged for several 
years and considered to be relatively precise, at least during periods of thermal 
neutrality (Moore et al., 2005a). Moreover, it is assumed to be independent of 
production (i.e. milk yield) levels (Tyrrell et al., 1991).  Net energy for lactation is 
calculated according to the NRC (2001) by the following equation: net energy for 
lactation = [(0.0929 x fat %) + (0.0547 x crude protein %) + (0.0395 x lactose %)] x 
milk production.  This equation is quite accurate assuming concentrations of fat, 
protein and lactose are all known (Weiss, 2002).  Positive and negative energy 
balance (PEBAL and NEBAL) respectively, represents theoretical differences 
between an animal gaining or losing BW.  Cows in early lactation lack the physical 
capacity to consume enough feed necessary to satisfy their energetic needs, and 
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consequently enter NEBAL. The most severe point of NEBAL is referred to as 
NEBAL nadir, which is commonly reached between the first and second weeks of 
lactation (Beam and Bulter, 1999).  Contrary to what is commonly reported by a 
number of papers (Broom, 1995; Veerkamp et al., 1998, 2000; Heuer, 2004), higher 
yielding cows experience a similar calculated NEBAL (severity, magnitude, etc.) 
when compared to lower producing herdmates (Vicini et al., 2002; Crooker et al., 
2006).  However, in a review of twenty studies, Grummer (1993) demonstrated great 
variability in the range in the number of days in milk (DIM) needed to reach PEBAL 
(7-105 DIM).  Grummer also attempted to correlate days with peak milk yield with 
the time to PEBAL.  Association relationships were small (r=.24 and r=.23, 
respectively) and he concluded that other factors besides energy outputs are 
responsible for time needed to reach PEBAL.  
Metabolic Disorders  
Production associated diseases may be considered a breakdown in various 
metabolic systems (Payne, 1972).  Peripartum dairy cattle experience a period of IN 
resistance, reduced feed intake, NEBAL, lipolysis, BW loss, hypocalcemia, and 
reduced immune function (LeBlanc, 2010).  In a review in 2006, Goff demonstrated 
that despite heightened efforts in health monitoring programs and veterinary care, 
the incidence of common metabolic disorders on dairy farms has not declined, and 
in fact the incidence rates of some health disorders have increased (Table 1.2).  As 
a consequence, interest persists in developing nutritional strategies that can partially 
mitigate diseases that are associated with NEBAL.  Whether the following disorders 
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(described below) are caused by NEBAL is debatable, but regardless the disorders 
are at least closely associated with energetic status and thus of nutritional 
importance (Figure 1.2). 
 
 
 
  
 
 
 
 
 
Figure 1.2:   Interrelationships between nutrition and disease in the periparturient 
dairy cow.  Adapted from Goff, 2006 
Table 1.2: Incidence of major health problem in US dairy herds in 1995 and 
2001 as a percentage of total number of cows or calves (modified from the 1996 
and 2002 NAHMS surveys; Adapted from Goff,   2006.)  
 Cattle affected, %  
 1995 2006 
Mastitis 13.4 14.7 
Lameness 10.5 11.6 
Retained placenta 7.8 7.8 
Milk fever 5.9 5.2 
Displaced abomasum 2.8 3.5 
Pre-weaning death 10.8 8.7 
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Displaced abomasum  
An abomasal displacement occurs when the abomasum distends, fills with 
fluid, gas or both causing the abomasum to migrate into an abnormal position 
(Svendsen, 1969).  Coppock (1972) fed high concentrate diets to cows in early 
lactation and was first to clearly identify a nutritional risk factor linked to occurrence 
of abomasal displacement.   In a study examining 156 affected cows, 86% of left 
displaced abomasums (DA) incidence was observed within two weeks prepartum to 
two weeks post-partum, with the higher incidence occurring ten days following 
parturition (Whitlock, 1969).  Displaced abomasums not only cause a direct cost of 
up to $200 per case, but also contribute to losses due to premature culling, lost 
production and even mortality (Eicker, 1995).  In addition, cows treated for a DA will 
produce 350 kg less milk on average during the month following treatment (Eicker, 
1995).  There are three factors believed to be responsible for the incidence of a DA.  
First, the rumen does not fill the void left by the retracting uterus, which leaves 
physical space for the abomasum to slide under it.  Second, the omentum attached 
to the omasum must have been stretched to permit movement under the rumen.  
Finally, abomasal gases (that are normally expelled into the rumen) accumulate due 
to impaired abomasal contractions, causing abomasal atony (Goff and Horst, 1997).  
Additionally, the reduction of DMI associated with the periparturient period could 
increase the risk of a DA due to decrease in rumen fill (Constable et al., 1992).  
Furthermore, cows that experience ketosis, retained placenta, metritis, or 
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hypocalcemia were at increased risk of experiencing a DA (Curtis et al., 1985; 
Massey et al., 1993).  Moreover, cows with an excessive BCS (>4.0) at parturition 
has been associated with a decreased DMI and subsequent increase in DA 
incidence rate (Dyk, 1995); it was also noted that these cows experienced fatty liver 
or ketosis more frequently.  The management practice of “lead feeding” or offering a 
diet with increased concentrate levels during the final two to three weeks prepartum 
has shown mixed effectiveness at reducing the number of left displaced abomasum 
(LDA).  Curtis and colleagues (1985) demonstrated that cows lead fed energy and 
protein were at a lower risk of LDA; odds ratio (OR) = 0.3 or 0.4, and ketosis (OR = 
0.2 to 0.8), respectively.   Correa and coworkers (1990) reported that cows lead fed 
concentrates were at increased risk for LDA (OR = 4.4), however the authors also 
mention that a portion of lead feeding programs studied in the survey had higher 
energy and calcium concentrations than recommended.  Robertson (1968) 
retrospectively studied low and high LDA risk herds and noted that higher grain 
amounts had been fed 4 to 6 weeks prepartum in high incidence herds.   
Dystocia 
Few studies have examined the relationship between BCS, a gross measure 
of EBAL, and dystocia. Most reports do not identify any significant relationship 
between BCS at calving and dystocia rates in multiparous Holstein dairy cows 
(Gearhart, 1990; Waltner, 1993; Berry et al., 2007).  Gearhart and colleagues and 
Berry and coworkers also reported no effect of BCS on retained placenta, metritis, or 
other metabolic or reproductive disorders.  Although no relationship has been 
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demonstrated between BCS and dystocia, cows that experienced dystocia or a 
stillbirth event had a greater BCS loss post-calving and a lower BCS at nadir (Berry 
et al., 2007b).   
Fatty Liver  
Fatty liver is the result of an imbalance in the hepatic flow of lipid.  In ruminant 
liver tissue there is insufficient fatty acid export as VLDL (Pullen et al., 1989).  Due to 
inadequate hepatic export a significant proportion of fatty acids are esterified and 
stored in the liver as TAG (Grummer, 1995) and severe TAG accumulation can lead 
to fatty liver syndrome (Grummer, 1993). The aforementioned TAG accumulation is 
caused by a lack of oxaloacetate.  Due to demand of oxaloacetate required for 
gluconeogenesis, acetyl-CoA entry into the hepatic tri-carboxylic acid (TCA) cycle is 
compromised (acetyl-coenzyme A combines with oxaloacetate to form citrate, 
(Krebs, 1966); acetyl-CoA is converted to acetoacetate and β-hydroxybutyrate 
through the ketogenesis cycle (Nelson and Cox, 2005).  This likely also down 
regulates fatty acid β-oxidation which contributes to an accumulation of hepatic TAG. 
Ketogenesis 
Ketone bodies are a by-product of fatty acid oxidation in hepatic tissue (Bell, 
1979; Baird, 1982).  Ketogenesis is the result of an increased metabolic demand for 
milk production which surpasses intake capabilities of transitioning dairy cows 
(Wagner and Loosli, 1967).  The mammary gland is an obligate glucose utilizer (in 
regards to lactose synthesis), therefore to support the demand for extra-mammary 
energy needs, adipose tissue is mobilized (Kronfeld et al., 1963).  This “glucose 
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sparing” is an evolution strategy to maximize milk synthesis during a period of 
inadequate nutrient intake.  Ruminants almost exclusively depend on hepatic 
gluconeogenesis to produce glucose, due to ruminal fermentation of dietary 
carbohydrates. The TCA cycle intermediate oxaloacetate plays a central role in 
hepatic gluconeogenesis (acetyl CoA combines with oxaloacetate to form citrate; 
Krebs, 1966) from propionate and amino acids (Schultz, 1968).   Thus during 
periods of increased glucose demand, there is a limit to the amount of fatty acids 
that can be oxidized by the TCA cycle   (Goff and Horst, 1997).  
Ketosis 
Ketosis is an increase in “ketone bodies” (β-hydroxybutyrate, acetoacetate 
and acetone) synthesis and they are exported from the liver to supply extra hepatic 
tissues with energetic substrates, or building blocks of mammary de novo fatty acid 
synthesis (Schultz, 1968; Littledike et al., 1981). Ketosis causes no change in body 
temperature, but decreases appetite, reduces milk yield, and deceases numerical 
BCS (Baird, 1982).  Subclinical ketosis is diagnosed as BHBA concentration of ≥12 
mg/dL, and clinical ketosis is defined as BHBA concentration >30 mg/dL (Ospina et 
al., 2010).  Subclinical ketosis represents an economic loss of approximately $78 per 
case (Geishauser et al., 2001).   
Rumen Acidosis 
Rumen acidosis, although not directly caused by NEBAL, is often associated 
with the transition period due to increased proportion of concentrates in the ration (a 
nutritional strategy to increase the energetic density of the diet to ameliorate effects 
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of NEBAL).  After the dry period (in which a high forage diet is typically fed), rumen 
papillae are generally shorter, which limits their absorptive capability, and therefore 
are less able to accommodate the sudden increase in volatile fatty acid (VFA) levels 
resulting from fermentation of a higher concentrate diet (Goff and Horst, 1997; Kleen 
et al., 2003).  The rumen VFA buildup causes a decrease in pH, which inadvertently 
changes the microbial population and this causes the number of lactic acid 
producing organisms to outnumber those that utilize it (Nocek, 1997).  
Consequently, lactic acid levels increase and clinical acidosis results.  
Hypocalcemia 
Hypocalcemia (i.e. milk fever) occurs when calcium leaves the blood to 
support milk synthesis at a greater rate than it can be replenished through the diet, 
skeletal stores, and renal conservation (Goff, 2005).  In a study utilizing 
mastectomized cows, Goff et al. (2002) determined that the mammary gland is fully 
responsible for inducing a state of hypocalcemia during the periparturient period.  In 
a commercial setting, the incidence of clinical milk fever is approximately 5%, while 
subclinical hypocalcemia (blood calcium concentration between 1.38 and 2 mmol/L) 
in the periparturient period is around 50% in multiparous cows (Horst et al., 2003).  
The decrease in blood calcium concentration impairs muscle contractile ability and 
ultimately causes cow “weakness”.  Blood calcium concentration is homeostatically 
regulated between 2.1 and 2.5 mmol/L in adult cows (Goff, 2008). Hypocalcemia, 
will trigger secretion of parathyroid hormone, which causes osteoclasts to release 
calcium, for the kidney to resorb calcium and stimulate renal production of the 
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hormone 1,25-dihydroxyvitamin D, necessary for efficient intestinal calcium uptake.  
Cows that develop clinical milk fever fail to sufficiently regulate these mechanisms.    
Endotoxemia 
Lipopolysaccharides (LPS) are endotoxins, a cell wall component of all gram-
negative bacteria, and cause the release of highly proinflammatory compounds. 
Lipopolysaccharides are released to the rumen fluid as a response to feeding high 
grain rations (Emmanuel et al., 2008; Khafipour et al., 2009; Zebeli and Ametaj, 
2009).  The transition period of the lactating dairy cow is marked by a sudden ration 
change, with the induction of increased concentrate diets beginning immediately 
following parturition.   Therefore, the transition cow may be at more of a risk of LPS 
infiltration than cows in established lactation.  
 The periparturient period is accompanied by a compromised immune system 
(Mallard et al., 1998).  The demands for copious milk production causes the early 
lactating cow to enter into a state of NEBAL, and this further exacerbates the risk for 
experiencing metabolic disease (Grummer 1993).  Several studies indicate that the 
occurrence of metabolic disease (i.e. fatty liver and ketosis) is accompanied by a 
broad scope immune system response (Targowski and Klucinski, 1983; Wentink et 
al., 1997; Suriyasathaporn et al., 1999; Zerbe et al., 2000).  For example, Zebeli and 
coworkers (2009) reported a positive correlation between the incidence of DA and 
RP and elevated plasma LPS levels.  However, LPS was induced via infusion on a 
limited number of cows (n=16).  Interestingly, in the same study average DMI and 
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milk yield of LPS challenged cows was reduced by 5 and 7 kg/d, respectively, 
however no changes in metabolites were observed. 
Other LPS inducing-research examined LPS in association with clinical 
mastitis.  Approximately 40% of the clinical cases of mastitis are caused by gram-
negative bacteria (Erskine et al., 1991; Ziv, 1992).  It is estimated that due to severe 
gram-negative mastitic infections, nearly 25% of infected cows will die or be culled 
as a result of exaggerated inflammatory responses (Jackson and Bramley, 1983; 
Eberhart, 1984). The most prevalent gram-negative pathogens associated with 
mastitis infection are Escherichia coli, Klebsiella pneumoniae, and various species of 
Enterobacter (Eberhart et al., 1979; Eberhart, 1984).  All of these bacterial species 
have LPS on the outer membrane. When cows were challenged with LPS, via 
intramammary injection, a substantial decrease in milk yield, increased body 
temperature, increased leukocyte production and elevated SCC were observed 
(Bannerman et al., 2003).  However, no studies to date have examined endogenous 
(i.e. non-challenged) LPS in association with metabolic disorders in the 
periparturient lactating dairy cow.   
Nutritional and Management Strategies to Mitigate Effects of NEBAL 
Grouping Management 
Currently a two-phase 60-day dry period is recommended, with increased 
energy provided (Mcal/kg NEL on a dry matter basis) in the ration during the final 
three weeks prepartum as opposed to the early dry period (NRC, 2001).  The 
objective of an energy-restricted diet during the early dry period is to mitigate 
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potential BW gain. It has been demonstrated that offering excessive dietary energy 
early in the dry period may have a negative carryover effect on lactational 
performance (Dann et al., 2003).  However, literature generally indicates that 
increasing dietary energy prepartum helps to maximize cow success during 
transition (Woodword et al., 1932; Campbell and Flux, 1948; Lees et al., 1948; 
Schmidt and Schultz 1959; Minor et al., 1998; Dan et al., 1999; VandeHaar et al., 
1999).  Research conducted by Contreras and colleagues (2004) observed that 
cows which had an initial BCS of 3.0 or less at dry off compared to a 3.5, had a 
tendency to have increased milk yield during the first five months of lactation.  
Additional studies support the concept of reduced BCS at dry off resulting in 
increased DMI and milk yield in the subsequent lactation (Gransworthy and Topps, 
1982a,b; Treacher et al., 1986; Garnsworthy and Jones, 1987; Domequ et al., 1997).  
Conjointly, published literature suggests cows with lower BCS at dry off, fed a 
reduced energy diet in early dry off, followed by a more energetically-dense ration 
approximately 21 days prepartum will have greater propensity to transition 
successfully as a result of increased DMI and possibly increased milk yield in early 
lactation (Overton and Waldron, 2004). 
DCAD 
  Prepartal diets with a negative dietary cation-anion difference (DCAD) 
reduces the risk for milk fever (Horst et al., 1997).  There have been several 
hypothesized causations of failure to maintain blood calcium homeostasis, however 
hypocalcemia primarily results from metabolic alkalosis and hypomagnesemia.  
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Metabolic alkalosis is the result of a greater proportion of blood cations to anions, 
typically induced by high potassium diets.  A high blood pH interferes with the ability 
of parathyroid hormone to effectively act on the bone and the kidney.  Due to this 
interference, hormone 1,25-dihydroxyvitamin D is not produced, bone calcium is not 
resorbed and the cow cannot properly maintain blood calcium levels.  
Hypomagnesemia results from a diet deficient in magnesium.  Magnesium serves as 
co-factor allowing the parathyroid hormone to stimulate cyclic AMP production.  
Compromising the ability of parathyroid hormone to act on target tissues will result in 
hypocalcemia.  To prevent hypocalcemia, and ultimately milk fever, it is necessary to 
decrease dietary cations, specifically potassium or increase dietary anions, 
particularly chloride during the prepartum period.  This induces metabolic acidosis, 
thus restoring the ability of parathyroid hormone to regulate blood calcium levels 
(Goff and Horst, 2003) 
Concentrate Feeding 
Post-partum dietary energy supplementation can be achieved through a 
variety of means: adding oils, tallow, by-pass fats (ca++ salts), propylene glycol, 
ionophores/monensin, concentrates, direct fed microbials, etc.  Each of these 
products either attempts to increase dietary energetic density or improves digestion 
efficiency resulting in improved energy availability. However, some of these 
methods, such as increasing the lipid content of the diet, can decrease palatability 
and could ultimately decrease DMI, and consequently have little or no increase on 
total energy intake.  
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As a result of the lower pre-fresh concentrate diet fed during the dry period, a 
reduction in rumen papillae length of up to 50% has been observed thereby 
markedly decreaseing the rumen’s absorptive surface area (Goff and Horst, 1997).  
The fresh cow is faced with an abrupt dietary change to a high concentrate lactation 
ration immediately post-partum. While lactate-producing bacteria respond quickly to 
the change in the diet, lactate utilizing bacteria lag behind and thus, lactate levels 
increase and this decreases pH, potentially initiating clinical rumen acidosis (Goff 
and Horst, 1997).   Due to these effects observed in early lactation, Rabelo and 
coworkers (2003) were one of several who suggested increasing the amount of Non-
Fiber Carbohydrate (NFC) during the dry period especially as parturition 
approaches.   
Feeding increased levels of concentrates during dry period may improve the 
rumen flora adaptation, increase rumen papillae length and width and, as a result, 
improve rumen VFA absorptive capacity, which may prime the rumen for a high 
starch lactation diet.  McNamara et al. (2003) demonstrated support for this concept 
when they noted an increased milk yield when dietary concentrate was raised from 4 
to 8 kg/d.  Evidence of potential benefit of high concentrate proportion was further 
supported in a review by Overton and Waldron (2004; Table 1.3).  Furthermore, 
increasing the digestibility of the concentrate can also have beneficial effects.  For 
example, Dann et al. (1999) reported a 2.9 kg/d increase in milk yield by feeding 
steam flaked corn (higher energy availability) throughout the transition period 
compared to cracked corn. 
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Ionophores 
Monensin sodium (Rumensin®) is a carboxylic polyether ionophore produced 
by a strain of Streptomyces cinnamonesis (Haney, 1967).  Monensin functions 
through binding to bacterial cell membranes causing an initial release of potassium 
from the cell and intake of hydrogen ions (Russell, 1996).  As a result, the bacterial 
cell must increase hydrogen ion export in order to maintain equilibrium (Donoho, 
1984).  In effect, this challenge to maintain equilibrium results in a shift in microbial 
population in the rumen (Bergen and Bates, 1984).  Monensin promotes an 
environment with an increased proportion of gram-negative organisms.  Gram-
negative organisms contain fumerate reductase, which produces succinate, and this 
Table 1.3: Effects of non-fiber carbohydrate percentage on production. 
 NFC, % DM  
Experiment Low High Effect of high NFC 
Grum et al., 1996 18 28 ↑pre-DMI 
Minor et al., 1998 24 44 ↑pre-DMI 
Mashek and Beede, 2000 35 38 ↓pre-BHBA 
Keady et al., 2001 13 28 ↑pre-DMI 
Holcomb et al., 2001 25 30 ↑pre-DMI 
Doepel et al., 2002 24 30 ↑post-DMI 
Rabelo et al., 2003 38 45 ↑pre-DMI 
 Table adapted from Overton and Waldron, 2004 
Nonfiber carbohydrate; 100 – [(NDF-NDICP) + CP + EE + Ash]; NRC, 2001 
Cows fed higher NFC prepartum continued on higher NFC diet post-partum 
Higher NFC increased milk yield only in 3rd lactation and greater cows 
Statistical trend. ↓↑   
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can be further metabolized to propionate (Bergen and Bates, 1984).  Due to the 
increase in propionate production, there is an increase in efficiency of energy 
digested and absorbed from the diet.  In addition, increased propionate production 
allows for increased glucose synthesis in monensin fed lactating cows (Baumgard et 
al., 2011).  Monensin offers additional benefits including modified feed intake, 
change in protein utilization, modified rumen fill and rate of passage, and other 
ruminal modes of action (Schelling, 1984).   
Propylene Glycol 
 
Propylene glycol serves as a highly digestible source of energy available as a 
feed supplement.  Drenching fresh cows with propylene glycol to treat ketosis is 
commonly practiced.  However, utilizing propylene glycol as a feed additive is fairly 
novel.  Propylene glycol functions through increasing plasma glucose 
concentrations; this is accomplished via decreasing peripheral tissue demand for 
glucose (Kirsten and Raun, 2007).  Further, propylene glycol reduces NEFA and 
liver triglyceride, thereby reducing plasma BHBA concentration (Grummer et al., 
2004).  A review by Nielsen and Ingvartsen (2004) states that “supplementing 
propylene glycol around calving and/or in early lactation had either unchanged, or a 
tendency toward increased milk yield”. 
Fat Supplementation 
Supplementing additional fat to the periparturient diet has been postulated to 
improve the energetic status the fresh cow.  Kronfeld (1982) believed that improving 
the energetic content of the diet through dietary fat, would in turn, minimize NEFA 
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mobilization and ultimately decrease the occurrence of ketosis.  Evidence supporting 
Kronfeld’s hypothesis was demonstrated by Doeple and coworkers (2002) when 
they observed decreased NEFA concentrations and decreased liver TAG in 
periparturient cows feed high energy diets. 
Increasing the dietary fat content can be achieved through a variety of 
strategies and products.  The type of fat supplemented appears to have an effect, as 
long-chain fatty acids are utilized as energy for peripheral tissues as well as energy 
for the mammary gland (Overton and Waldron, 2004). Adding products such as 
vegetable oils can impair fiber digestion and rumen function, but feeding an equal 
quantity of oil in the form of oilseeds typically does not have negative effects 
(Coppock and Wilks, 1991).  Results from production research evaluating fat 
supplementation are varied.  A review by Schingoethe and Casper (1991) 
demonstrated an average 2.8% increase in milk yield during the addition of a range 
of fat sources, with a 4.6% increase in milk yield over the whole lactation.   
Fat supplementation is common in both early lactation diets and during 
periods of heat stress.  Regardless of lactational stage, heat-stressed cows will 
typically enter into NEBAL, due to a reduction in DMI and increased maintenance 
costs (Baumgard and Rhoads, 2007).  Fiber digestion, although important in 
maintaining proper rumen function, increases basal metabolic heat production 
(Nayeri et al., 2011) when compared to starch and fat digestion.  Dietary fat has 
commonly been viewed as a nutritional strategy to ameliorate the negative effects 
associated with heat stress (i.e. reduced DMI and the heat increment of feeding 
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generated by dietary fiber).  However, the efficacy of dietary fat inclusion in heat 
stress diets has been variable (Table 1.4). 
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 Table 1.4:  Effects of fat type supplementation on production parameters during heat stress.   
          
Reference Fat Type RT RR DMI FE MY MF MP Metabolites 
1 SFA/UFA ↑ ↑ ↓ ↑ ↔ ↑ ↔ ↑NEFA 
2 SFA ↓ ↔ ↔ ↑ ↑ ↑ ↑ ↓NEFA 
3 SFA NM NM ↔ ↔ ↑ ↓ ↑ NM 
4 LCFA ↔ ↔ ↔ ↑ ↑ ↔ ↓ ↓NEFA 
5 SFA ↔ ↔ ↔ ↔ ↔ ↔ ↔ NM 
6 LCFA/Tallow ↔ ↔ ↔ ↔ ↔ ↔ ↔ NM 
7 SFA NM NM ↔ ↔ ↑ ↔ ↔ ↔ 
8 SFA/UFA ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ 
 
 
NM: Not Measured 
↑: Increase 
↓: Decrease 
↔: No Change 
SFA: Saturated Fatty 
Acids 
UFA: Unsaturated Fatty 
Acids 
LCFA: Long-Chain Fatty 
Acids 
 
 
 
 
RT: Rectal Temperature 
RR: Respiratory Rate 
DMI: Dry Matter Intake 
FE: Feed Efficiency 
MY: Milk Yield 
MF: Milk Fat 
MP: Milk Protein 
NEFA: Non-Esterified Fatty Acids 
 
 
 
1. Moallem et al., 2010 
2. Wang et al., 2010 
3. Warntjes et al., 2008 
4. Drackely et al., 2003 
5. Chan et al., 1997 
6. Knapp and Grummer, 1991 
7. Skaar et al., 1989 
8. Moody et al.,1967 
 
Table adapted from Nayeri et al., 2011 
2
3
 
2
3
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Conjugated Linoleic Acid 
Conjugated Linoleic Acid (CLA) represents a combination of positional and 
geometric isomers of linoleic acid with conjugated double bonds.  Conjugated linoleic 
acids were first discovered as a “functional food” by Pariza and co-workers when they 
demonstrated that geometric isomers of linoleic acid found in hamburger possessed anti-
carcinogenic effects (Pariza et al., 1979).  According to Belury (2002), CLA has been 
associated with an array of potential human health benefits.  Furthermore, the National 
Academy of Science reported that “conjugated linoleic acid is the only fatty acid shown 
unequivocally to inhibit carcinogenesis in experimental animals” (NRC, 1996).  
Subsequent studies confirmed the previously observed anti-carcinogenic effects, and 
also discovered additional potential health opportunities (i.e. diabetes, etc.; Belury, 
2002).  Consequently, tremendous effort has been placed on increasing CLA levels in 
the human diet via ruminant derived food products. 
CLA in Ruminant Products 
 
Ruminant food products supply the greatest amount of CLA in human diets 
(McGuire and McGuire, 1999); milk fat representing the richest source of natural CLA 
(Parodi, 1977).  In 1935, Booth and colleagues were the first to characterize ruminant 
lipids as containing fatty acids with conjugated double bonds.  Later, Parodi (1977) 
determined that the primary CLA isomer in milk fat was cis-9, trans-11 octadecadienoic 
acid.  However, in theory a number of different CLA isomers are possible, each differing 
in the position and geometric orientation of the double bond pairs (Bauman et al., 1999).   
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The cis-9, trans-11 CLA found in milk and meat fat of ruminant animals originates 
from one of two sources (Bauman et al., 2000).  One form is made during ruminal 
biohydrogenation of linoleic acid (Figure 1.3) and the second is synthesized by the 
animal’s tissues from a biohydrogenation intermediate (Griinari and Bauman, 1999; 
Bauman et al., 2000).  Because of its rumen origin, lipid produced by monogastric 
animals contain little or no CLA (Bauman and Griinari, 2001).  
Rumen biohydrogenation is utilized by rumen microorganisms to modify a 
potentially toxic substrate (unsaturated fatty acids) to a more inert molecule (saturated 
fatty acids; Harfoot and Hazlewood, 1988).  Through conversion of unsaturated fats, the 
rumen microbes are also able to dispose H+ from the reducing environment (Byers, 
1988).  The hydrolysis of the ester linkages is the initial step in fat digestion by bacteria 
Figure 1.3: Biochemical pathways for the biohydrogenation of linoleic and 
linolenic acids in the rumen (adapted from Harfoot and Hazlewood, 1997). 
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to form triglycerides, phospholipids and glycolipids (Bauman et al., 2003).  Once 
hydrolysis has occurred, microbial biohydrogenation of unsaturated free fatty acids 
occurs.  The major substrates in rumen biohydrogenation are linoleic and linolenic acid 
(Bauman et al., 2003).   
CLA and Transition Period 
It has been well documented (Bell, 1995; Grummer, 1995; Drackley, 1999) that 
the early lactating cow enters NEBAL as a result of insufficient energy intake to meet the 
required demands for milk synthesis and maintenance.  A logical strategy is to 
supplement the diet with high-energy feedstuffs.  However, increasing the energetic 
density of the diet has been largely unsuccessful in eliminating or reducing NEBAL.  For 
instance, supplementing the diet with additional fat will increase the energetic density of 
the ration, but can affect palatability and often decreases DMI (Staples et al., 1998).  The 
elimination of NEBAL may not be attainable, as it has also been proposed that 
increasing the energetic density of the diet will simply increase milk production in such a 
manner that the improvement to EBAL status is negated (Santos et al., 2008).   
A novel approach to improving EBAL status has been the discovery of the trans-
10, cis-12 isomer of CLA which inhibits milk fat synthesis (Baumgard et al., 2000) in a 
dose dependent manner (de Veth et al., 2004) in both cows on pasture based systems 
(Mackle et al., 2003; Kay et al., 2006) and in cows fed TMR diets (Bernal-Santos et al., 
2003; Odens et al., 2007) in various stages of lactation.  Fat is the most energetically 
expensive component of milk to produce: daily milk fat secretion in early lactating cows 
can represent up to 35% of net energy intake (Bauman and Currie, 1980).  Milk fat 
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depression (MFD) immediately post-partum is possible but a larger dose of the trans-10, 
cis-12 CLA is required compared to established lactation (Perfield et al., 2002; Moore et 
al. 2004).  Therefore, the MFD capabilities of trans-10, cis-12 CLA prove beneficial by 
improving calculated NEBAL through a temporary reduction in milk fat output (Table 1.5).  
Despite MFD, milk protein and milk yield are not decreased with the supplementation of 
trans-10, cis-12 CLA and milk fat content will return to similar levels of production 
following the termination of trans-10, cis-12 CLA supplementation (Table 1.5). 
The magnitude and severity of NEBAL is associated with a variety of impaired 
reproductive indices (Beam and Butler, 1999).  Improved fertility responses have been 
observed when cows were supplemented with CLA during early lactation.  Among these 
positive responses are a reduced interval to first ovulation, increased plasma insulin-like 
growth factor 1 (IGF-1) and increased pregnancy rate (Bernal-Santos et al., 2003; 
Cataneda-Gutierrez, 2005; Cataneda-Gutierrez, 2007).  These results were confirmed in 
a meta-analysis of five studies by de Veth et al. (2009).               
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Table 1.5: Summary of results obtained from feed supplementation of rumen-inert 
conjugated linoleic acid (RI-CLA) during the transition period 
CLA Duration Milk Yield Milk Fat Milk Protein  
g/d Days kg/d % g/d % g/d Reference 
0
1 
154
2
 44.3 3.60
a 
1570 2.77 1214 Bernal-Santos et al., 2003 
40  47.1 3.15
b 
1452 2.74 1264  
0 106
7
 21.9
a
 4.20
a
 913a 3.40 731
a
 Back and Lopez-Villalobos, 2004 
120  24.2
b
 3.10
b
 748b 3.40 810
b
  
0
1
 31
5 
33.4 4.57
a 
1465
a
 4.02 1208 Moore et al., 2004 
62
 
 33.7 3.97
a,b 
1288
a,b
 3.49 1191  
125  35.5 3.32
b 
1146
a,b
 3.76 1234  
187
 
 34.3 3.10
b 
1026
b
 3.68 1218  
0 77
3 
40.3 3.49
a 
1380 2.89 1140 Selberg et al., 2004 
0
4 
 42.5 3.46
a 
1390 2.81 1120  
90  41.5 2.99
b 
1190 2.82 1150  
0 105
6
 40.3
a
 3.49
a
 1395
a
 3.10 1250 Shingfield et al., 2004 
110  47.4
b
 1.92
a
 901
b
 2.30 1420  
0
1 
84
8
 43.4 3.82
a 
1650
a
 2.85 1240 Castaneda-Gutierrez et al., 2005 
31.6  43.8 3.43
b 
1460
b
 2.81 1220  
63.2  43.8 3.08
c
 1300
c
 2.79 1200  
0 63
9 
19.4
a 
5.12
a 
998
a
 3.68 720 Kay et al., 2006a 
0
1
  22.5
b 
4.76
b 
1045
a
 3.54 790  
150  22.1
b 
3.35
c 
738
b
 3.60 794  
0 49
11 
35.57 4.27
a 
1408.7
a 
3.20 1051 Odens et al., 2007 
600  38.23 3.16
b 
1091.1
b 
3.40 1182  
600
10 
 38.50 3.49
b 
1164.5
b 
3.50 1158  
43
1 
79
12 
50.6
a 
-
 
1680
a 
- 1560 Moallem et al., 2010 
50  52.9
b 
-
 
1530
b 
- 1570  
0 60
13 
26.5 4.26
a 
1080
a 
3.12 810 Hutchinson et al., 2011 
80  26.5 3.78
b 
980
b 
3.07 780  
0 60
14 
24.7
a 
- 910
a 
- 810 Hutchinson et al., 2011 
51  27.2
b 
- 840
b 
- 850  
a,b,c
 Superscripts within a row indicate significant differences (P < 0.05) within a study 
1
 Calcium salts 
2
 Treatment initiated 14 d prior to calving through 140 d post-partum 
3
 Treatment initiated 28 d prior to calving through 49 d post-partum 
4
 Treatment contained 150 g/d of mixed trans c-18:1 isomers 
5
 Treatment initiated 10 d prior to calving through 21 d post-partum 
6
 Treatment initiated at calving through 105 d post-partum 
7
 Treatment initiated 5 d post calving through 111 d post-partum 
8
 Treatment initiated 21 d prior to calving through 63 d post-partum 
9
 Treatment initiated 27 d prior to calving through 36 d post-partum 
10
Treatment supplemented 600 g/d until 10 post-partum rate then decreased to 200 g/d 
11
Treatment initiated 9 prior to calving through 40 d post-partum 
12
Treatment initiated at 21 DIM through 100 DIM 
13
Treatments initiated at calving through 60 DIM 
14
Treatments initiated at calving through 60 DIM 
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Vitamin and Mineral Supplementation 
 Intense metabolic demands of the periparturient period increase the production of 
reactive oxygen species (ROS; Sordillo, 2005) and reduce immunological capacity 
(Overton and Waldron, 2004). An increase in oxidative stress occurs when ROS 
production exceeds antioxidant defense mechanisms (Spears and Weiss, 2007). 
Immune cells are particularly sensitive to oxidative stress and can produce large 
amounts of ROS when stimulated (Allison and Laven, 2000).  This enhanced sensitivity 
was also identified by Sordillo and coworkers (1995) when they reported that leukocytes 
from immunosuppressed cows had a hypersensitivity to a challenge and increased 
production of proinflammatory cytokines. Several vitamins and trace minerals are 
involved in antioxidant and immune system defense system, and a dietary deficiency in 
one of these essential nutrients may negatively affect broad scope immune cell defense 
mechanisms. 
Zinc 
Zinc (Zn) is the only transition metal that acts as cofactor for more than 300 
different enzymes (Rink and Gabriel, 2000).  Additionally, Zn is a biologically essential 
element required for cell growth, development, differentiation, homeostasis, connective 
tissue growth and maintenance, DNA synthesis, RNA transcription, cell division and cell 
activation (Chasapis et al., 2011). Zinc participates in pathways/reactions for carbonic 
anhydrase, carboxypeptidase, alcohol dehydrogenase, glutamic dehydrogenase, lactic 
dehydrogenase, D-glyceraldahyde-3-phospate dehydrogenase, alkialine phosphate, and 
others (Vallee, 1959; Ott et al., 1965; Hsu and Anilane, 1966; Li, 1966; Forbes, 1967; 
Snaith and Levvy, 1968).  Generally, the effects of Zn (either deficiency or increased 
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supplementation) will be mediated through changes or efficiency alterations to enzymatic 
reactions involving Zn. 
Animals that are Zn deficient have reduced feed intake, grow at a slower rate, and 
subsequently have reduced feed efficiency (Miller et al., 1965).  Zinc deficient calves are 
lethargic, have reduced or absent of wound healing capabilities, and are more likely to 
have a secondary infection which can lead to death (Miller and Miller 1960, 1962).  
Clinical Zn deficiency is diagnosed as inflammation of the nose and mouth with sub-
mucous hemorrhages, unthrifty appearance, rough coat, stiffness of the joints, and 
swelling of the feet.  Furthermore, cracks can develop in the skin of coronary bands 
around the hooves which later become deep fissures, dry or cracked skin on the ears, 
and cracking of the skin around the nostrils (Miller and Miller 1960, 1962) in Zn deficient 
animals.  The earliest observed sign of Zn deficiency is a reduction in DMI.  
Consequently, the first sign of proper Zn supplementation is restored DMI (Quarterman, 
1968; Quarterman et al., 1969).   
Zinc absorption initiates from the intestinal mucosa with the majority of absorption 
occurring in the proximal portion of the intestinal tract (Hiers et al., 1968; 1969; Miller and 
Cragle, 1965).  Further, it is believed Zn absorption by the mucosa is a much more rapid 
process compared to the transfer of Zn into the blood stream (Sahagian et al., 1967).        
Zinc levels are homeostatically regulated (Hambidge, 2000) and several studies 
have demonstrated a reduction in dietary Zn causes a marked increase in intestinal 
absorption and decrease in Zn excretion (Baer and King, 1984; Flanagan, 1984; Jackson 
et al., 1984; Fung et al., 1997).   Early research attempting to create a Zn deficient diet to 
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cause mortality in rats failed (Newell and McCollum, 1933); this was likely due in part to 
the aforementioned absorptive efficiency categorized some 50 years later. 
A host of kinetic modeling studies followed the characterization of Zn absorption 
(Pattison and Cousins, 1986; Raffaniello et al., 1992; Reyes, 1996) and have given rise 
to the discovery of Zn transporters; the first was ZnT1 discovered in 1995 by Palmiter 
and Findley.  In mammalian systems, a minimum of 14 Zn transporters have been 
identified as being responsible for cellular influx or efflux (Luizzi and Counsins, 2004).  
The transporters can be further divided into two families based upon function: ZnT 
solute-linked carrier 30 (SLC30), and Zip family solute-linked carrier 39 (SLC39; (Luizzi 
and Counsins, 2004).  Transporters ZnT and Zip differ greatly in cellular regulation of 
homeostasis.   Cytoplasmic Zn concentrations are reduced by ZnT transporters through 
efflux or packaging into intracellular vesicles. Conversely, Zip transporters increase 
intracellular cytoplasmic Zn concentration by promoting extracellular and, perhaps 
vesicular Zn transport into the cytoplasm (Luzzi and Cousins, 2004). 
Dairy Zn Requirements 
The NRC (2001) recommends dietary Zn for fresh cows producing 35 kg of milk to 
be 73 mg/kg of DMI.   A number of factors can affect dietary Zn availability such as form, 
dietary antagonists and age of the animal (Miller and Miller, 1963).  Zinc concentration in 
body tissues can vary widely especially during periods of deficiency (Blackmon et al., 
1965).  In brain and muscle tissue, Zn concentration remains steady even in times of 
severe deficiency (Miller, 1969).  Contrastingly, during periods of dietary deficiency, Zn 
content in hair, bone, liver, lung, kidney, spleen, pancreas, and blood is markedly 
reduced (Miller et al., 1965, 1966, 1968, 1969).  However, in most tissues the range 
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between deficient and normal Zn concentration is substantial, thus making clinical 
diagnosis of Zn deficiency difficult.  However, milk, which usually contains 4 ppm Zn, can 
serve as an indicator of Zn supplementation (Archibald, 1944), and milk Zn concentration 
is subject to manipulation through dietary supplementation.   
Zinc and Immune Function 
A collection of research generated from human subjects and laboratory animals 
suggests that Zn deficiency impairs the immune response (Chesters, 1997).  Studies 
indicate decreased natural killer cell activity during periods of Zn deficiency (Fernandes, 
1979; Allen et al., 1983).   B-lymphocyte antibody responsiveness is inhibited by Zn 
deficiency (Fraker et al., 1978; Luecke et al., 1978; DePasquale-Jardieu et al., 1984). 
Monocytes from Zn deficient mice had impaired killing of intracellular parasites, which 
was rapidly corrected in vitro by adding Zn (Wirth et al., 1989).  Furthermore, Zn deficient 
animals exhibit increased spontaneous and toxin-induced apoptosis in multiple cell types 
(Dinsdale and Williams, 1977; Zalewski and Forbes, 1993).  Additionally, in human 
subjects Zn supplementation has been identified as a powerful immune system booster, 
with efficacy dependent upon dose and treatment duration.  A physiological dose of Zn 
for a short period (1 month) restores immune efficiency in Down’s syndrome individuals 
with subsequent reduction (50%) of infectious episodes.  Moreover, Mocchegiani and 
Muzzioli (2000) observed no appearance of first opportunistic infection in HIV patients 
supplemented with Zn.  However, in animal studies the effect of Zn supplementation has 
shown mixed results.  In a limited number of studies, Zn supplementation at marginally 
deficient levels had no effect on immune responses (Droke and Spears, 1993; Droke et 
al., 1993).  However, when Chirase et al. (1991) challenged finishing steers with 
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infectious bovine rhinotracheitis virus (IBRV), it was found that supplementing dietary Zn 
improved the immune response.   Sordillo and co-workers (1997) suggested that 
intrammamary infections (IMI) develops through an impaired epithelial cell function, 
causing either alterations in keratin plug formation or impaired phagocytes’ ability to 
move to the site of infection.  Periparturient cows are at increased risk for developing of 
IMI due to elevation of BHBA concentrations which causes impaired of leukocyte 
function (Suryiyasathapron et al., 2000).  Research from New Zealand reported 
impairment of leukocyte function in over conditioned heifers due to increased udder 
edema (Compton et al., 2007).  Zinc plays a key role in the enzymatic process of 
maintaining epithelial cell integrity (Sordilo et al., 1997). 
Organic Trace Mineral Supplementation 
Cattle are often supplemented with trace minerals and traditionally they have 
been in the form of inorganic salts with limiting degrees of bioavailability, consquently 
organic trace mineral (OTM) supplementation is of interest due improved uptake and 
retention (Nockels et al., 1993).  Several studies reported OTM have increased biological 
availability when compared to inorganic forms (Uchida et al., 2001; Yost et al., 2002; 
DeFrain et al., 2009).  In a meta-analysis of twenty-two studies, Rabiee and coworkers 
(2010) demonstrated increases in total milk yield, 3.5% fat corrected milk (FCM), and 
increased pregnancy rate for cows supplemented with OTM.  Further, Spain (1993) 
reported decreased rates of new IMI in cows supplemented with OZ, and attributed this 
reduction to enhanced keratin lining in the teat canal.  O’Dohoghue and Boland (2002) 
reported that cows supplemented with OTM had reduced somatic cell count (SCC) when 
compared to inorganic Zn supplementation.  An increase in milk production and 3.5% 
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FCM, but no effect on milk SCC was reported by Nocek and colleagues (2006) when 
minerals were supplied entirely in the organic form. Popovic (2004) reported reduced 
milk SCC in dairy cows fed OZ compared to cows fed a similar amount of Zn sulfate 
prepartum and early lactation. Finally, OTM beneficially influenced total immunoglobulin 
levels in both colostrum and blood serum of new-born calves, and in the dams 
demonstrated increased milk production and a marked (34%) decrease in milk SCC 
(Kinal et al., 2007).  Therefore, there appears to be consistency within the literature that 
suggests OTM, and specifically OZ, may enhance the immune system and improve 
mammary health (and thus milk quality). 
Effects of Supplemental OZ on Lactation Parameters 
 Zinc, an essential mineral, was established decades ago as being necessary for 
growth and health in animals (NRC, 2001).  The degree to which Zn status is believed to 
effect lactational performance has increased in accordance with our understanding of its 
biological role.  The NRC has increased recommended dietary Zn levels for lactating 
dairy cows in its last two publications (NRC 1989, 2001).  One possible explanation for 
increased Zn recommendations from the NRC could be to new information regarding 
antagonists that reduce Zn availability, specifically dietary minerals such as iron, sulfur, 
calcium, and other heavy metals (NRC, 2001).   
Organic chelation of minerals, to amino acid complexes has been demonstrated 
to improve bioavailability (Wedekind et al., 1992).   Further, OTM have been shown to 
have greater retention in the body compared to inorganic mineral sources (Nockels et al., 
1993).   As discussed above, supplementing OTM often elicits positive responses on 
lactational parameters (Rabiee et al., 2010).   Commonly, in studies investigating OTM 
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supplementation, all trace minerals are provided entirely in the organic form.   As a 
result, it is difficult to attribute the beneficial effects of OTM to enhanced availability of 
one specific mineral.  However, the contribution of Zn to milk synthesis and thus the 
reason for the improved production variables should not be overlooked, as Zn is a 
component of over 300 enzymes spanning six classes (Dibley, 2001).  Zinc is involved in 
carbohydrate metabolism, protein synthesis, cell repair and vitamin A transport and 
utilization (Miller et al., 1988; Dibely, 2001; Hunt and Groff, 1990; Kim et al., 1998).    
In a review of literature (Table 1.6) the effect of OZ on lactational parameters are 
presented.  Interestingly, according to the literature, results of OZ supplementation on 
production variables are highly heterogeneous.  In six of the 16 experiments, OZ 
improved milk production.  Reasons for both the variation between experiments and the 
mechanism by which OZ increases milk synthesis are poorly understood.  Furthermore, 
very few studies have examined how OZ supplementation affects energetic parameters 
such as DMI or plasma energetic metabolites.    
In the vast majority of studies, SCC was either maintained or reduced by OZ 
supplementation (Table 1.6).  As already mentioned, Zn is required for maintenance of 
skin integrity, stabilization of cell membranes, and activation of the immune system 
(Miller and Madsen, 1992).  Further, a low Zn status can decrease milk quality and result 
in higher SCC and increase IMI (Aguilar and Jordan, 1990; Galton, 1990).  It seems 
plausible that improved Zn availability could enhance the immune system function or 
efficacy and thereby reduce the immune system’s contribution to maintenance energy 
requirements and increasing the energy available for milk synthesis.   
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Interestingly, of the studies examined (Table 1.6), none attempted to evaluate the 
Zn or other trace mineral status prior to experimental initiation.  Assessing Zn status 
becomes important as Zn dietary deficiencies result in decreased growth, milk 
production, feed efficiency, immune function, and reproduction.  However, accurately 
assessing the Zn status can be difficult due to increasing absorption during periods of 
deficiency, animal age, varying tissue affinity and rapid transport.  In experiments 
examining the effect of additional Zn supplementation, the initial Zn status is important 
because it is difficult to discern whether the positive production responses are the result 
of increased Zn supplementation (above minimum requirements) or simply the that the 
Zn supplementation treatments were now meeting the animals Zn requirement (i.e. the 
controls were being fed a Zn restricted diet).  
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Table 1.6:  Summary of results obtained from feeding Zn Amino Acid Complex on 
lactational production parameters.   
Reference N MY Fat Pro Lac SCC DMI FE Metabolites 
1 18 ↔ ↔ ↔ ↔ ↓* ↔ NM NM 
2 79 NM NM NM NM ↔ NM NM NM 
3 44 ↑ ↔ ↔ ↔ ↓ ↔ NM NM 
4 22 ↔ ↔ ↔ ↔ ↓* ↔ NM NM 
5 98 ↑ ↔ ↑ ↔ ↓ NM NM NM 
6 36 ↔ ↓ ↔ ↔ NM NM NM Mixed 
7 40 NM NM NM NM ↔ NM NM NM 
8 24 ↔ ↔ ↔ ↔ ↔ ↔ NM NM 
9 58 NM NM NM NM ↓ NM NM NM 
10 40 ↑* ↔ ↔ NM ↔ NM NM NM 
11 36 ↔ ↔ ↔ NM ↔ NM NM NM 
12 76 ↔ ↔ ↔ ↔ ↓ NM NM NM 
13 76 ↑ ↔ ↔ ↔ ↔ NM NM NM 
14 120 ↑ ↑ ↔ NM ↑ NM NM NM 
15 48 ↑ ↑ ↔ ↑ ↓ NM NM NM 
16 15 ↔ NM NM NM ↔ NM NM NM 
NM:  Not 
measured 
↑:  Increased 
↔:  No change 
↓:  Decreased 
* Denotes 
tendancy 
 
n:  Experimental number 
MY:  Milk yield 
Fat:  Milk fat 
Pro:  Milk protein 
Lac:  Milk lactose 
SCC:  Somatic cell count 
DMI:  Dry matter intake 
FE:  Feed efficiency  
 
 
1.  Schobhanirad et al., 2010 
2.  Andersson and Leon, 2003 
3.  Cope et al., 2003 
4.  Salama et al., 2001 
5.  Schwimmer and Braun, 2001 
6.  Smith et al., 1999 
7.  Whitaker et al., 1997 
8.  Jones, 1995 
9.  Galton, 1990 
10.  Kellogg et al., 1989 
11.  Moore et al., 1989 
12.  Aguilar et al., 1988 (A) 
13.  Aguilar et al., 1988 (B) 
14.  Kincaid et al., 1985 
15.  Wealsby et al., 1985 
16.  Kincaid et al., 1984 
 
 
 
 
38 
 
Maximizing Potential for Peak Milk Yield 
Peak milk yield is frequently achieved while the cow is in NEBAL (Baumgard et al., 
2007; Figure 1.4) but whether or not insufficient dietary energy is preventing maximum 
milk production is unclear.  Through dietary strategies such as trans-10, cis-12 CLA and 
OZ supplementation it may be possible to alleviate NEBAL, and NEBAL mediated 
impaired immune function.  The broad objectives of this thesis were to evaluate different 
dietary strategies to improve periparturient production, health, and reproductive indices 
in lactating Holstein cows.      
 
 
EBAL 
Actual 
Milk Yield 
Theoretical 
Milk Yield 
Figure 1.4:  Relationship of milk yield and EBAL in early lactation; with 
dotted line signifying an EBAL of 0.  Adapted from Baumgard et al., 2007. 
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CHAPTER 2 
Effects of Dietary Supplementation with trans-10, cis-12 Conjugated Linoleic Acid 
(CLA) on Production, Reproduction and Culling Parameters in Transitioning 
Holstein Cows 
ABSTRACT 
Conjugated linoleic acid (CLA), specifically the trans-10, cis-12 CLA isomer, 
inhibits milk fat synthesis. During NEBAL, moderate CLA-induced milk fat depression 
(MFD) increases milk yield, and improves the overall calculated energetic status of the 
transition cow.  Although assessable to producers in Europe and Canada, the trans-10, 
cis-12 CLA isomer is not yet commercially available in the United States.  The study 
objective was to determine the effects of protected (lipid-encapsulated) trans-10, cis-12 
CLA on milk production, health, culling frequency and reproduction in a large commercial 
dairy application.  Multiparous (n=299) and primiparous (n=180) Holstein cows were 
blocked by 305 previous mature equivalent milk yield and parity and assigned to 1 of 3 
dietary treatments which began 21 d prior to expected calving dates and ceased at 15 
DIM ± 3 d: 1) no CLA supplementation, Con, 2) 50 g/h/d prepartum followed by 150 g/h/d 
through 15 DIM, CLA1 (Lutrell®, BASF, Germany), and 3) 50 g/h/d prepartum followed 
by 75 g/h/d through 15 DIM, CLA2.  Cows were housed at the Lake Breeze Dairy, Fon 
du Lac, WI.  There was no overall CLA effect on milk yield, but both CLA treatments 
reduced (P < 0.05) milk fat content similarly when compared to control fed cows.  CLA-
induced MFD became significant by d 8 (5.3%) and continued until 30 (11.6%) DIM. 
There were little or no treatment effects on other milk components. Feeding either CLA 
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dose had no effect on measured variables of metabolism, health, reproductive 
parameters nor culling events.  The reduction in milk energy output likely indicates an 
improved calculated energetic status of the transition cow, but why this did not parlay 
into increased production variables remains ill-defined. Further research is necessary to 
determine dietary CLA’s applicability in the US dairy industry.   
 
INTRODUCTION 
Early lactation cows are typically unable to consume enough dietary energy to meet 
daily requirements for milk production and maintenance costs, and consequently enter 
into a state of calculated net NEBAL.  The severity, magnitude and day of NEBAL nadir 
(~4-9 DIM) have been associated with increased susceptibility to metabolic disorders 
and subsequent reproductive failure (Canfield and Butler, 1990; Drackley, 1999; Buckley 
et al., 2003). Dietary strategies attempting to mitigate the effects of NEBAL during early 
lactation have centered on increasing dietary energy via adding concentrates or fats.  
However this approach is often associated with negative effects such as rumen acidosis 
and reduced fiber digestion, which may ultimately reduce DMI thereby compounding the 
energetic problem (Hayirli and Grummer, 2004).  A different nutritional strategy to 
improve NEBAL involves modifying the EBAL equation through manipulating energy 
expenditure, and this has been accomplished via decreasing milk fat synthesis.  Milk fat 
is the most energetically expensive milk component to synthesize (50% of total milk 
energy; Tyrell and Reid, 1965) and the milk component most easily manipulated by 
management (Bauman and Davis, 1974; Bauman and Griinari, 2001).  Therefore, 
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regulated EBAL via controlled milk fat depression (MFD) could serve a management tool 
to improve transition period success.   
Conjugated linoleic acid, specifically the trans-10, cis-12 isomer, is a potent 
inhibitor of milk fat synthesis during established lactation (Loor and Herbein, 1998; 
Chouinard et al., 1999b; Baumgard et al., 2000, 2002a).  Subsequent studies revealed a 
much larger CLA dose (~3 x) is required to induce MFD in early lactation compared to 
established lactation (Moore et al., 2004; Kay et al., 2006a).  In both trials (Moore et al., 
2004; Kay et al., 2006a), MFD was induced a few days post-calving (2-4 DIM); the 
magnitude of MFD progressed as lactation advanced and maximum MFD was not 
obtained until approximately the second week of lactation.  Kay and colleagues  (2006) 
and Odens and co-workers (2007) also reported that moderate CLA-induced MFD 
caused a positive response in milk yield, however as MFD became more severe (>35-
40%), the milk yield response diminished.  The increase in milk yield during mild MFD is 
probably a consequence of “spared” energy from the synthesis of fat and would likely 
only be observed during NEBAL (i.e. early lactation or in some pasture management 
situations; Baumgard et al., 2006). 
All the aforementioned experiments were conducted at controlled research and 
academic institutions utilizing a small number of animals. Whether or not controlled MFD 
during the periparturient period improves transition period indices of production, 
reproduction, and health on a large farm is not known.  Study objectives were to 
investigate if supplementing CLA to periparturient cows would induce MFD and improve 
long term production, reproduction, and health or culling parameters in a commercial 
dairy.   
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MATERIALS AND METHODS 
The Iowa State University Institutional Animal Care and Use Committee approved 
all procedures involving animals.  Multiparous (n=299) and primiparous (n=180) Holstein 
cows were blocked by 305 previous mature equivalent milk yield and parity then 
assigned to 1 of 3 dietary (lipid-encapsulated CLA) treatments (Table 2.1) which began 
21 d prior to expected calving and ceased at 15 DIM ± 3 d: 1) no CLA supplementation, 
Con; 2) 50 g/h/d prepartum followed by 150 g/h/d through 15 DIM, CLA1 (Lutrell®, 
BASF, Germany); and 3) 50 g/h/d prepartum followed by 75 g/h/d through 15 DIM, 
CLA2.  Both CLA treatments delivered 5 g of trans-10, cis-12 CLA prepartum and 15 and 
7.5 g of trans-10, cis-12 CLA post-partum for CLA1 and CLA2, respectively.  Cows were 
housed and managed at the Lake Breeze Dairy, Fon du Lac, WI.  After 15 ± 3 DIM, cows 
left the “fresh pen” and were co-mingled in the “high pen”, but data collection on each 
animal continued until 200 DIM (Figure 2.1).  Lake Breeze Dairy could not logistically 
handle three treatments simultaneously, so CLA2 feeding was initiated immediately 
following Con and CLA1 treatments ceased.  The trial was conducted from April 2010 
until February 2011.  Cows in Con and CLA1 treatments calved from April 29, 2010 to 
May 29, 2010; cows in the CLA2 treatment calved from June 17, 2010 to July 2, 2010.   
All production, reproduction, health and culling parameters were recorded through 
200 DIM in Dairy Comp 305 (DC 305, Valley Ag Software, Tulare, CA).  All cows were 
fed TMR diets that were iso-energetic and iso-nitrogenous and formulated by Nutrition 
Professionals Inc. (Neenah, WI) to meet or exceed the predicted requirements (NRC, 
2001) of energy, protein, minerals and vitamins.  Corn silage was the main forage source 
and ground corn was the primary concentrate (Table 2.2).  The TMR was sampled 
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weekly, composited monthly and analyzed via wet chemistry methods (AgSource 
Cooperative Service, Bonduel, WI).  Fresh feed was offered daily at 0800 h and pen feed 
intake was determined daily.  
Cows were milked thrice daily and milk yield was recorded and condensed into 
weekly means for statistical analysis.  Milk samples were obtained weekly on all cows for 
three weeks post freshening with subsequent monthly sampling up to 200 DIM for milk 
composition analysis.  Sampling and milk composition analysis was conducted by 
AgSource Cooperative Services (Bonduel, WI).  Because milk samples were collected 
based on calendar dates instead of DIM, milk composition samples were assigned a 
theoretical DIM for each sample dependent on cow’s actual day in milk.  For example, if 
cows were sampled anywhere between 1-8 DIM that sample was assigned to time point 
8 DIM; samples obtained from 9-16 DIM were assigned to time point 16 and so forth for 
the each weekly milk composition sample.     
Lake Breeze Dairy staff recorded all health, culling and reproductive parameters.  
An Ov-Synch program with a voluntary waiting period of 75 d was utilized by Lake 
Breeze Dairy with a select group of cows bred via standing heat prior to 75 d.  Sera and 
plasma samples were obtained on a subset of cows (n=15/trt) at d -21, 0, 21, 60 ± 3 
relative to calving.  Plasma and sera analysis was conducted by Land O’Lakes (Arden 
Hills, MN; Table A-1.3).  Body condition scores were determined on the same subset of 
cows that plasma and sera samples were obtained from and estimated independently by 
two trained individuals using a five-point system (Wildman et al., 1982) and scores were 
averaged for statistical purposes.  Observations and general health records were 
recorded throughout the study.  Cows were removed from statistical analysis if their 
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previous days carried calf value was less that 260 (i.e. they calved early) or if cows were 
moved to an incorrect pen following freshening. 
Statistical Analysis 
  The data set was analyzed in two parts based on lactation stage: early lactation 
(weeks 1 to 3 of lactation for milk yield and DIM 8-59 for milk composition; Table 2.3) and 
the entire lactation performance (days 1 to 200 DIM; Table 2.4). Milk yield was analyzed 
by repeated measures using the PROC MIXED procedure of SAS (2005) with an 
autoregressive covariance structure and week of lactation or DIM serving as the 
repeated effect.  The model contained week of lactation, treatment, parity, week of 
lactation x treatment interactions and parity x week of lactation x treatment interactions.  
Cows were the random effect and week of lactation, treatment, parity, week of lactation x 
treatment interaction and parity x week of lactation x treatment interactions were the 
fixed effects.  Milk components were analyzed by repeated measures using the PROC 
MIXED procedure of SAS (2005) with an autoregressive covariance structure and day of 
lactation as the repeated effect.  Health frequency and culling events were analyzed by 
using the ANOVA procedure of SAS (2005). The model contained treatment interactions.  
Standard errors of the mean are reported and differences considered significant when P 
<0.05 unless otherwise stated. 
 
RESULTS 
There was an early lactation treatment effect on milk yield (P < 0.01), as milk 
production for CLA2-fed cows was reduced at weeks two and three (P < 0.05; Figures 
2.2; 2.3) compared to Con and CLA1-fed cows.  However, there was no overall 
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treatment effect on established lactation (1-200 DIM) milk production (P > 0.10; Figures 
2.4; 2.5).  
  Milk fat percentage was decreased (P < 0.05) in early lactation by CLA 
supplementation.  Despite differing doses, the magnitude and temporal pattern of MFD 
did not differ between CLA treatments (Figure 2.6).  The CLA-induced MFD became 
significant for both CLA treatments at 8 DIM (P < 0.05; 5.3%) and continued to become 
more severe by 15 DIM (8.5%) and reached its maximum level (11.6%) at 30 DIM 
(Figure 2.7). By 59 DIM, milk fat percentage in both CLA treatments returned to levels 
similar to the Con-fed cows (Figures 2.8; 2.9).   
Milk protein percentage was initially increased at 8 DIM by CLA2 supplementation 
(P  < 0.01; Figures 2.10; 2.11) but was decreased (3.1%; P < 0.05) compared to Con-fed 
cows at 15 DIM.  CLA2-fed cows had reduced milk protein content (6.8%; Figure 2.11) at 
30 DIM compared to both Con and CLA1.  However, there was no overall treatment 
effect on established lactation milk protein percentage (P > 0.10; Figures 2.12; 2.13).   
Milk lactose content for CLA-supplemented cow was decreased at 8 DIM (P < 
0.01; Figures 2.14; 2.15).  The milk lactose content for CLA2-fed cows tended to be 
decreased at 15 DIM (2.5%; P = 0.07) there was no difference in milk lactose at 30 DIM 
(P > 0.10; Figures 2.14; 2.15).  Despite early lactation treatment x time interactions, 
there was no overall treatment effect on established lactation milk lactose protein 
percentage (P > 0.10; Figures 2.16; 2.17). 
Milk solids-not-fat (SNF) percentage was increased at 8 DIM by CLA1 
supplementation compared to Con-fed cows (P < 0.01; Figure 2.18) there was no 
difference between CLA1 and CLA2 at 8 DIM (P = 0.11).  There was at tendency for 
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SNF percentage to be reduced by CLA2 supplementation (P = 0.05) at 15 DIM 
compared to Con-fed cows. The decrease in milk SNF percentage for CLA2-fed cows 
continued to progress at 30 DIM (2.4%; Figure 2.18).  By 59 DIM any difference across 
treatments had been eliminated. There was no overall effect of CLA treatment on SNF 
percentage (Figures 2.20; 2.21). 
Reproductive performance is summarized in Table 2.5.  Reproduction appeared 
to be largely unaffected by CLA supplementation.  Services per conception and DIM at 
conception were not different (P > 0.10).  Furthermore, conception rate to first service 
(36.3%) and second service (38.2%) was similar between treatments.  However, the 
proportion of CLA2-supplemented cows pregnant at 200 DIM was numerically greater 
(~15%) compared to Con and CLA1-fed cows. 
Supplementing CLA had no effect on somatic cell linear number (SCCLN) in early 
lactation or established lactation (P > 0.10; Figures 2.22-2.23).  Feeding CLA did not 
affect the incidence of health disorders (Figure 2.24) including DA (3%), ketosis (18%), 
lameness (12%), mastitis (23%), metritis (11%), or retained placenta (8%). No treatment 
effect was detected for low production, reproduction, injury, mastitis or lameness culling 
parameters (Table: 2.6; Figure 2.25).      
 
DISCUSSION 
Periparturient dairy cows often enter into a calculated state of NEBAL because 
dietary intake is insufficient to meet the demand for both maintenance and galactopoesis 
(Drackley, 1999).  During late gestation a coordinated, and well-orchestrated, metabolic 
shift must occur to achieve a successful transition period and thus a profitable lactation 
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(Bauman and Currie et al., 1985).  Failure to successfully partition nutrients and carry out 
the homeorretic process results in an increase in the number of days to reach NEBAL 
nadir and a more severe NEBAL and both lead to reproductive failure, metabolic 
disorders and reduced production (Canfield and Butler, 1990; Beam and Butler, 1999; 
Buckley et al., 2003; Baumgard et al., 2006).   
A number of trials have demonstrated that the trans-10, cis-12 CLA isomer is a 
potent inhibitor of milk fat synthesis during established lactation (Loor and Herbein, 1998, 
2003; Chouinard et al. 1999a, 1999b; Giesy et al., 2002; Perfield et al., 2002; Moore et 
al., 2005b,c; Medeiros et al., 2000; Mackle et al., 2003; Kay et al., 2006b).  Dietary CLA 
supplementation is an effective management strategy in situations where mandated milk 
fat quotas dictate saleable milk volume (i.e. Canada and much of Europe). However, in 
order for CLA-induced MFD to be a commercially viable management tool in the US 
dairy industry it must be able to reduce milk fat synthesis immediately post-partum (and 
thus improve EBAL parameters) and logistically fit the “fresh” pen (Baumgard et al., 
2006).  Fresh pen feeding strategies usually have less energy (specifically reduced 
concentrates) to allow time for the rumen to adapt to a more energy dense (higher 
starch) ration and are usually only fed for two to four weeks immediately post-partum.  In 
the aforementioned situations, CLA was supplemented well past the ~15 d fresh period 
and into the high lactating pens.  Milk fat is the most energetically expensive component 
of milk to synthesize and represents of up to 35% of dietary intake (Bauman and Currie, 
1980).   Additionally milk fat is also economically valuable and the dairy producer is not 
likely to tolerate MFD, without revenue compensation (i.e. increased milk yield, improved 
fertility or reduction in metabolic disorders).   
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Early transition period investigations fed CLA at similar dosage rates to what was 
supplemented in established lactation (Giesy et al., 1999; Bernal-Santos et al., 2003; 
Selberg et al., 2004; Castaneda-Gutierrez et al., 2005) and results indicate that CLA did 
not induce MFD until the 3rd or 4th week of lactation.  Since then, a number of studies 
(Moore et al., 2004; Kay et al., 2006; Odens et al., 2007) demonstrated that MFD could 
be achieved within days after parturition and the current trial confirms this as milk fat 
content was reduced by 8 DIM (the first day at which milk composition was determined).  
The magnitude of CLA-induced MFD became more severe as lactation progressed and 
the largest differential (12%) between CLA and Con-fed cows occurred at 30 DIM (Figure 
2.7).  Interestingly, 30 DIM was approximately two weeks after CLA supplementation 
ceased.  In previous studies that supplemented CLA before or immediately after 
parturition, MFD did not occur immediately post-partum. Moore and coworkers (2004) 
suggested that the mammary gland is less sensitive to CLA-induced MFD during very 
early lactation, possibly due to a resistance of milk synthesis genes to manipulation; 
likely for evolutionary purposes.   
Also, it is worth noting that there were no differences in milk fat content between 
the two CLA doses, despite the fact that CLA2 delivered only half as much trans-10, cis-
12 CLA post-partum as the CLA1 treatment (15 vs. 7.5 g/h/d). This lack of a difference in 
milk fat content is hard to interpret as there is a clear dose response relationship 
between trans-10, cis-12 CLA and the level of MFD in early lactation (Moore et al., 
2004).  However, comparing the two CLA doses is difficult because they were not fed 
simultaneously and the results are confounded with time of year. Regardless, 
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determining why there were no differences between CLA1 and CLA2 treatments in milk 
fat content is of interest.  
Previous reports indicate that mild CLA-induced MFD in early lactation may 
partition energy and nutrients towards increased milk synthesis (Kay et al., 2006;Odens 
et al., 2007; Huctchinson et al., 2011). However, results from our experiment indicate no 
difference in milk yield between Con and CLA1-fed cows despite mild MFD (i.e. 5-12%).  
In fact, CLA2-fed cows had reduced milk yield during early lactation compared to Con 
and CLA1-fed cows. However, as stated previously, interpreting data from the CLA2-fed 
cows is difficult as they were not fed the supplement simultaneously with Con and CLA1-
fed cows.  As a consequence, the CLA2 treatment is confounded with time and this 
includes obvious weather and season effects but also other unbeknownst issues (i.e. 
forage variation, labor issues, etc.).  
 A treatment x DIM interaction was observed for milk protein and lactose as CLA2-
fed cows had reduced protein and lactose content in early lactation despite producing 
less milk during this time.  These differences are likely attributable to seasonal effects as 
CLA2-fed cows calved in the summer as several studies (Chouinard et al., 1999a, 
1999b; Baumgard et al., 2001; Perfield et al., 2002; Peterson et al., 2002; Moore et al., 
2004; Odens et al., 2007; Hutchinson et al., 2011) indicate that CLA supplementation 
does not alter the content of other milk components.  
Reproductive performance was largely unaffected by CLA supplementation as 
there were no difference between conception rates at the first and second service.  This 
is in contrast to a recent small metal-analysis report (5 studies and 212 cows)  that 
indicated increased pregnancy rates and decreased days to conception in CLA-fed cows 
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(de Veth et al., 2009). There was an increase in the proportion of cows pregnant by 200 
DIM for cows fed CLA2, which would correlate well with results of other CLA 
supplementation studies (Bernal-Santos et al., 2003; Castaneda-Gutierrez et al., 2005; 
Medeiros et al., 2010).  However, due to the aforementioned confounding factors 
associated with CLA2 it is difficult to attribute this effect totally to CLA supplementation 
(i.e. it is likely this difference could be attributed to external factors).   
Despite the presumably improved calculated energetic status, feeding CLA had 
no effect on measured health parameters.  To our knowledge, the effects of CLA on 
health parameters have not been directly measured in previous trials.  It has been 
suggested that metabolic diseases are a result of NEBAL and compounded by the 
severity and magnitude of NEBAL nadir (Beam and Butler, 1999; Drackley, 1999).  
Although we did not directly measure or calculate EBAL, we assume cows fed both CLA 
treatments had improved EBAL parameters, so it is not clear why health indices were not 
improved. Possible explanations may include that the traditional dogma associating 
NEBAL with poor health is not accurate. For example, high producing cows and low 
producing cows both enter into similar calculated states of NEBAL (Vicini et al., 2002; 
Crooker et al., 2006).  Assuming high production does not cause metabolic disorders 
(i.e. an uncoupling of EBAL status and health), it in turn advocates for a closer 
association between EBAL and the efficiency of nutrient partitioning.  Under this 
assumption, it seems plausible that CLA would not ameliorate the occurrence of 
metabolic diseases, as CLA functions as an energy conversation tool (via MFD) rather 
than a nutrient-partitioning agent.   Again, given the aforementioned assumption 
regarding CLA’s possible ineffectiveness as a nutrient partitioning agent it is not 
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surprising that CLA did not influence the frequency of culling events.  The likelihood that 
CLA would have an effect on the entire lactation’s culling parameters is further minimized 
by the short time frame in which it was supplemented (ceasing at 15 DIM).  Following the 
move to the high lactating pen any effect of CLA on culling would only be an indirect and 
retrospective measure.  
An additional reason why the two CLA treatments did not improve health indices 
is that the CLA doses were insufficient to evoke enough MFD to cause positive 
responses.  However, this appears unlikely, the CLA dosage rates utilized in this trial (15 
and 7.5 g/h/d) are similar to that of previous published literature.  Additionally, the 
maximum dosage rate in this study was greater than previous reports that demonstrated 
improved milk yield (de Veth et al., 2006; Moallem et al., 2010).   Possible rationale for 
this observation could be damage to the lipid capsule (via product handling, grinding, 
heat etc.).  Damage to the lipid encapsulation could result in the trans-10, cis-12 CLA 
isomer being released in the rumen and becoming biohydrogenated.  This may explain 
why MFD was not as severe as we anticipated and the likely reason why milk yield, 
reproduction and health were not improved in this study.  
      
CONCLUSION 
The present study demonstrates that supplementing CLA during the transition 
period reduced milk fat content in early lactation, but the resultant presumed improved 
energy status did not impact other aspects of transition period success.  Further 
research is required to determine appropriate CLA supplementation levels to elicit 
52 
positive response on production parameters through the transition period in a 
commercial setting.  
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Table 2.1:  CLA treatment distribution. 
 Treatment  
Cow Variable Control CLA1 CLA2 
Prepartum Lutrell® 0 50 g/h/d 50 g/h/d 
Post-partum Lutrell® 0 150 g/h/d 75 g/h/d 
Enrolled in Trial, # 159 161 160 
Multiparous1, # 96 98 105 
Primiparous1, # 62 63 55 
Mean P305 ME1, kg 12,619 12,795 12,877 
Lactation1 2.06 1.89 2.3 
Removed for DCC<260, # 9 12 13 
Culled, # (%) 20 (12.6) 28 (17.3) 26 (16.3) 
Removed b/c incorrect pen, 9 22 0 
Completed Trial (200 DIM), 121 99 123  
1Prior to treatment initiation 
Figure 2.1:  Lake Breeze Dairy Farm experimental design schematic. 
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Table 2.2:  Prefresh and early lactation ration ingredients and composition.1 
 Composition Pre-partum  Fresh Pen 
 Ingredient, kg of expected DMI 
expected D 
Control CLA  Control CLA1 CLA2 
    Corn Silage 6.7 6.7  4.9 4.9 4.7 
    Haylage  2.0 2.0  2.2 2.2 2.6 
    CUD Control Mix 1.5 1.5  - - - 
    Ground Corn 1.1 1.1  3.0 3.0 3.2 
    Hay 0.8 0.8  1.1 1.1 1.0 
    Straw 0.2 0.2  - - - 
    Lac Mix - -  3.0 3.0 3.1 
    Dry Corn Gluten - -  1.2 1.2 1.2 
Chemical analysis, % of DM       
    Crude protein, % 13.5 13.4  17.0 17.0 17.2 
    RDP, %CP - -  61.0 61.0 61.5 
    RUP, %CP - -  38.9 38.9 38.4 
    ADF, % 22.2 22.6  18.0 18.0 18.0 
    NDF, % - -  27.8 27.8 27.2 
    NSC, % 40.8 40.8  39.6 39.6 39.7 
   Crude fat
a
, % - - 
 5.0 5.0 5.0 
    NEL
L
a
 Mcal/kg 1.65 1.65  1.73 1.73 1.73 
    Luterell, g 0 50  0 150 75 
1Values represent an average of samples collected and composited throughout the trial.   
55 
 
 
Table 2.3:  Effect of CLA on early lactation milk production parameters. 
 Treatment  P 
Parameter Con CLA1 CLA2 SEM TRT TRT 
x WOL 
TRT x DIM x 
Parity 
Contrast 
Milk Yield, kg/d 28.93
 
 28.80
 
27.07
 
0.61 0.06 0.03 0.94 0.15 
Milk Composition        
Fat, % 4.02
a
 
3.74
b
 
3.72
b
 0.06 <0.01 <0.01 0.78 <0.01 
Protein, % 3.15 3.13 3.12 0.03 0.16 <0.01 0.25 0.53 
Lactose, %
 
4.77 4.75 4.72 0.01 0.20 0.05 0.52 0.12 
SNF
2
, %
 
8.83 8.85 8.76 0.05 0.38 <0.01 <0.01 0.54 
SCCLN
3
 2.55
 
2.62
 
2.84
 
0.19 0.23 0.66 0.77 0.20 
1
Milk composition averaged over 60 d post-partum period, milk yield average over 21 d post partum 
2 
Solids-nonfat 
3
Somatic Cell Count Linear Number 
a,b
 Values within rows with differing superscripts indicate P < 0.05 
 
 
 
 
Table 2.4:  Effect of CLA on established lactation milk production parameters. 
 Treatment  P 
Parameter Con CLA1 CLA2 SEM TRT TRT 
x WOL 
TRT x DIM x 
Parity 
Contrast 
Milk Yield, kg/d 39.54
 
 39.86
 
39.63
 
0.42 0.86 0.05 0.82 0.61 
Milk Composition        
Fat, % 3.48
a
 
3.37
b
 
3.36
b
 0.03 0.05 <0.01 0.77 <0.01 
Protein, % 3.02 2.98 3.00 0.02 0.72 <0.01 0.12 0.53 
Lactose, %
 
4.84 4.84 4.84 0.02 0.97 <0.01 0.25 0.12 
SNF
2
, %
 
8.76 8.76 8.74 0.03 0.91 <0.01 <0.01 0.65 
SCCLN
3
 2.32
 
2.19
 
2.50
 
0.10 0.12 0.58 0.97 0.63 
1
Milk composition and milk yield average over 200 d post-partum 
2 
Solids-nonfat 
3
Somatic Cell Count Linear Number 
a,b
 Values within rows with differing superscripts indicate P < 0.05 5
5
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Table 2.6: Effect of CLA on health and culling events. 
 Treatment  P 
Health Event Control CLA1 CLA2 SEM Trt 
DA1, % (#) 3 (2) 4 (4) 2(1) 1.4 0.54 
Ketosis, % (#) 20 (16) 16 (16) 20 (16) 3.5 0.99 
Lameness, % (#) 10 (12) 15 (15) 12 (15) 1.2 0.51 
Mastitis, % (#)  26 (32) 23 (23) 34 (43) 4.0 0.08 
Metritis, % (#) 9 (7) 9 (9) 17 (13) 2.8 0.23 
Retained Placenta, % (#) 6 (4) 6 (6) 12 (9) 2.3 0.30 
Culling Events      
Total Culls, % 12.7 17.0 16.3 2.0 0.55 
Low Production, % 5.2 4.0 12.5 5.0 0.49 
Reproductive, % 0.0 0.0 8.0 3.0 0.15 
Injury or Other, % 63.0 56.0 50.0 6.0 0.69 
Mastitis, % 26.3 28.0 16.6 9.0 0.62 
Lameness, % 5.2 12.0 12.5 6.0 0.70 
1Displaced Abomasum      
Table 2.5:  Effect of CLA on reproductive performance.   
 Treatment  P 
Parameter Con Med High  Trt 
DIM at Conception 112 111 119     0.26 
Services per conception          2.09          2.03           2.11     0.90 
Concep. rate to first service, % (#) 36.1 (47/130) 35.5 (43/121) 37.4 (46/123)       - 
Concep. rate to second service, % (#) 36.1 (30/83) 37.1 (29/78) 41.5 (32/77)       - 
Overall Percentage Pregnant, %, (#) 82.3 (107/130) 79.3 (96/121) 96.7 (119/123)       - 
5
6
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Figure 2.2:  Temporal pattern of early lactation milk yield by parity (A) and treatment 
(B) from cows supplemented with conjugated linoleic acid (CLA).  Control (Con) fed 
cows received no CLA supplementation, CLA1 cows were supplemented 150 g/h/d 
of Lutrell® post-partum and CLA2 cows were supplemented 75 g/h/d of Lutrell®.  
Both CLA1 and CLA2 were supplemented 50 g/h/d prepartum.  Treatment initiation 
began 21 d prior to calving and ceased at 15 DIM ± 3 d. Values represent LS means 
for the control, CLA1, and CLA2 supplementation. 
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Figure 2.3:  Temporal pattern of early lactation milk yield by parity (A) and treatment 
(B) from cows supplemented with conjugated linoleic acid (CLA).  Control (Con) fed 
cows received no CLA supplementation, CLA-fed cows were supplemented with 
either 150 g/h/d or 75 g/h/d of Lutrell® post-partum. Treatment initiation began 21 d 
prior to calving and ceased at 15 DIM ± 3 d. Values represent LS means for the 
control and CLA supplementation. 
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Figure 2.4:  Temporal pattern of established lactation milk yield by parity (A) and 
treatment (B) from cows supplemented with conjugated linoleic acid (CLA).  Control 
(Con) fed cows received no CLA supplementation, CLA1 cows were supplemented 
150 g/h/d of Lutrell® post-partum and CLA2 cows were supplemented 75 g/h/d of 
Lutrell®.  Both CLA1 and CLA2 were supplemented 50 g/h/d prepartum.  Treatment 
initiation began 21 d prior to calving and ceased at 15 DIM ± 3 d. Values represent 
LS means for the control, CLA1, and CLA2 supplementation. 
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Figure 2.5:  Temporal pattern of established lactation milk yield by parity (A) and 
treatment (B) from cows supplemented with conjugated linoleic acid (CLA).  Control 
(Con) fed cows received no CLA supplementation, CLA-fed cows were 
supplemented with either 150 g/h/d or 75 g/h/d of Lutrell® post-partum. Treatment 
initiation began 21 d prior to calving and ceased at 15 DIM ± 3 d. Values represent 
LS means for the control and CLA supplementation. 
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Figure 2.6:  Temporal pattern of early lactation milk fat percentage by parity (A) and 
treatment (B) from cows supplemented with conjugated linoleic acid (CLA).  Control 
(Con) fed cows received no CLA supplementation, CLA1 cows were supplemented 
150 g/h/d of Lutrell® post-partum and CLA2 cows were supplemented 75 g/h/d of 
Lutrell®.  Both CLA1 and CLA2 were supplemented 50 g/h/d prepartum.  Treatment 
initiation began 21 d prior to calving and ceased at 15 DIM ± 3 d. Values represent 
LS means for the control, CLA1, and CLA2 supplementation. 
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Figure 2.7:  Temporal pattern of early lactation milk fat percentage by parity (A) and 
treatment (B) from cows supplemented with conjugated linoleic acid (CLA).  Control 
(Con) fed cows received no CLA supplementation, CLA-fed cows were 
supplemented with either 150 g/h/d or 75 g/h/d of Lutrell® post-partum. Treatment 
initiation began 21 d prior to calving and ceased at 15 DIM ± 3 d. Values represent 
LS means for the control and CLA supplementation. 
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Figure 2.8:  Temporal pattern of established lactation milk fat percentage by parity 
(A) and treatment (B) from cows supplemented with conjugated linoleic acid (CLA).  
Control (Con) fed cows received no CLA supplementation, CLA1 cows were 
supplemented 150 g/h/d of Lutrell® post-partum and CLA2 cows were supplemented 
75 g/h/d of Lutrell®.  Both CLA1 and CLA2 were supplemented 50 g/h/d prepartum.  
Treatment initiation began 21 d prior to calving and ceased at 15 DIM ± 3 d. Values 
represent LS means for the control, CLA1, and CLA2 supplementation. 
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Figure 2.9:  Temporal pattern of established lactation milk fat percentage by parity 
(A) and treatment (B) from cows supplemented with conjugated linoleic acid (CLA).  
Control (Con) fed cows received no CLA supplementation, CLA-fed cows were 
supplemented with either 150 g/h/d or 75 g/h/d of Lutrell® post-partum. Treatment 
initiation began 21 d prior to calving and ceased at 15 DIM ± 3 d. Values represent 
LS means for the control and CLA supplementation. 
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Figure 2.10:  Temporal pattern of early lactation milk protein percentage by parity 
(A) and treatment (B) from cows supplemented with conjugated linoleic acid (CLA).  
Control (Con) fed cows received no CLA supplementation, CLA1 cows were 
supplemented 150 g/h/d of Lutrell® post-partum and CLA2 cows were supplemented 
75 g/h/d of Lutrell®.  Both CLA1 and CLA2 were supplemented 50 g/h/d prepartum.  
Treatment initiation began 21 d prior to calving and ceased at 15 DIM ± 3 d. Values 
represent LS means for the control, CLA1, and CLA2 supplementation. 
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Figure 2.11:  Temporal pattern of early lactation milk protein percentage by parity 
(A) and treatment (B) from cows supplemented with conjugated linoleic acid (CLA).  
Control (Con) fed cows received no CLA supplementation, CLA-fed cows were 
supplemented with either 150 g/h/d or 75 g/h/d of Lutrell® post-partum. Treatment 
initiation began 21 d prior to calving and ceased at 15 DIM ± 3 d. Values represent 
LS means for the control and CLA supplementation. 
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Figure 2.12:  Temporal pattern of established lactation milk protein percentage by 
parity (A) and treatment (B) from cows supplemented with conjugated linoleic acid 
(CLA).  Control (Con) fed cows received no CLA supplementation, CLA1 cows were 
supplemented 150 g/h/d of Lutrell® post-partum and CLA2 cows were supplemented 
75 g/h/d of Lutrell®.  Both CLA1 and CLA2 were supplemented 50 g/h/d prepartum.  
Treatment initiation began 21 d prior to calving and ceased at 15 DIM ± 3 d. Values 
represent LS means for the control, CLA1, and CLA2 supplementation. 
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Figure 2.13:  Temporal pattern of established lactation milk protein percentage by 
parity (A) and treatment (B) from cows supplemented with conjugated linoleic acid 
(CLA).  Control (Con) fed cows received no CLA supplementation, CLA-fed cows 
were supplemented with either 150 g/h/d or 75 g/h/d of Lutrell® post-partum. 
Treatment initiation began 21 d prior to calving and ceased at 15 DIM ± 3 d. Values 
represent LS means for the control and CLA supplementation.  
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Figure 2.14:  Temporal pattern of early lactation milk lactose percentage by parity 
(A) and treatment (B) from cows supplemented with conjugated linoleic acid (CLA).  
Control (Con) fed cows received no CLA supplementation, CLA1 cows were 
supplemented 150 g/h/d of Lutrell® post-partum and CLA2 cows were supplemented 
75 g/h/d of Lutrell®.  Both CLA1 and CLA2 were supplemented 50 g/h/d prepartum.  
Treatment initiation began 21 d prior to calving and ceased at 15 DIM ± 3 d. Values 
represent LS means for the control, CLA1, and CLA2 supplementation. 
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Figure 2.15:  Temporal pattern of early lactation milk lactose percentage by parity 
(A) and treatment (B) from cows supplemented with conjugated linoleic acid (CLA).  
Control (Con) fed cows received no CLA supplementation, CLA-fed cows were 
supplemented with either 150 g/h/d or 75 g/h/d of Lutrell® post-partum. Treatment 
initiation began 21 d prior to calving and ceased at 15 DIM ± 3 d. Values represent 
LS means for the control and CLA supplementation.  
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Figure 2.16:  Temporal pattern of established lactation milk lactose percentage by 
parity (A) and treatment (B) from cows supplemented with conjugated linoleic acid 
(CLA).  Control (Con) fed cows received no CLA supplementation, CLA-fed cows 
were supplemented with either 150 g/h/d or 75 g/h/d of Lutrell® post-partum. 
Treatment initiation began 21 d prior to calving and ceased at 15 DIM ± 3 d. Values 
represent LS means for the control and CLA supplementation.  
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Figure 2.17:  Temporal pattern of established lactation milk lactose percentage by 
parity (A) and treatment (B) from cows supplemented with conjugated linoleic acid 
(CLA).  Control (Con) fed cows received no CLA supplementation, CLA-fed cows 
were supplemented with either 150 g/h/d or 75 g/h/d of Lutrell® post-partum. 
Treatment initiation began 21 d prior to calving and ceased at 15 DIM ± 3 d. Values 
represent LS means for the control and CLA supplementation.  
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Figure 2.18:  Temporal pattern of early lactation milk SNF percentage by parity (A) 
and treatment (B) from cows supplemented with conjugated linoleic acid (CLA).  
Control (Con) fed cows received no CLA supplementation, CLA1 cows were 
supplemented 150 g/h/d of Lutrell® post-partum and CLA2 cows were supplemented 
75 g/h/d of Lutrell®.  Both CLA1 and CLA2 were supplemented 50 g/h/d prepartum.  
Treatment initiation began 21 d prior to calving and ceased at 15 DIM ± 3 d. Values 
represent LS means for the control, CLA1, and CLA2 supplementation.  
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Figure 2.19:  Temporal pattern of early lactation milk SNF percentage by parity (A) 
and treatment (B) from cows supplemented with conjugated linoleic acid (CLA).  
Control (Con) fed cows received no CLA supplementation, CLA-fed cows were 
supplemented with either 150 g/h/d or 75 g/h/d of Lutrell® post-partum. Treatment 
initiation began 21 d prior to calving and ceased at 15 DIM ± 3 d. Values represent 
LS means for the control and CLA supplementation.  
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Figure 2.20:  Temporal pattern of established lactation milk SNF percentage by 
parity (A) and treatment (B) from cows supplemented with conjugated linoleic acid 
(CLA).  Control (Con) fed cows received no CLA supplementation, CLA1 cows were 
supplemented 150 g/h/d of Lutrell® post-partum and CLA2 cows were supplemented 
75 g/h/d of Lutrell®.  Both CLA1 and CLA2 were supplemented 50 g/h/d prepartum.  
Treatment initiation began 21 d prior to calving and ceased at 15 DIM ± 3 d. Values 
represent LS means for the control, CLA1, and CLA2 supplementation.  
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Figure 2.21:  Temporal pattern of established lactation milk SNF percentage by 
parity (A) and treatment (B) from cows supplemented with conjugated linoleic acid 
(CLA).  Control (Con) fed cows received no CLA supplementation, CLA-fed cows 
were supplemented with either 150 g/h/d or 75 g/h/d of Lutrell® post-partum. 
Treatment initiation began 21 d prior to calving and ceased at 15 DIM ± 3 d. Values 
represent LS means for the control and CLA supplementation.  
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Figure 2.22:  Temporal pattern of established lactation SCCLN by parity (A) and 
treatment (B) from cows supplemented with conjugated linoleic acid (CLA).  Control 
(Con) fed cows received no CLA supplementation, CLA1 cows were supplemented 
150 g/h/d of Lutrell® post-partum and CLA2 cows were supplemented 75 g/h/d of 
Lutrell®.  Both CLA1 and CLA2 were supplemented 50 g/h/d prepartum.  Treatment 
initiation began 21 d prior to calving and ceased at 15 DIM ± 3 d. Values represent 
LS means for the control, CLA1, and CLA2 supplementation. 
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Figure 2.23:  Temporal pattern of established lactation milk SCCLN by parity (A) 
and treatment (B) from cows supplemented with conjugated linoleic acid (CLA).  
Control (Con) fed cows received no CLA supplementation, CLA-fed cows were 
supplemented with either 150 g/h/d or 75 g/h/d of Lutrell® post-partum. Treatment 
initiation began 21 d prior to calving and ceased at 15 DIM ± 3 d. Values represent 
LS means for the control and CLA supplementation.  
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Figure 2.24:  Effect of treatment on health incidence frequency from cows supplemented with 
conjugated linoleic acid (CLA).  Control (Con) fed cows received no CLA supplementation, CLA1 
cows were supplemented 150 g/h/d of Lutrell®
 
post-partum and CLA2 cows were supplemented 75 
g/h/d of Lutrell®. Both CLA1 and CLA2 were supplemented 50 g/h/d prepartum. Treatment initiation 
began 21 d prior to calving and ceased at 15 DIM ± 3 d. Values represent LS means.  
 
 
Figure 2.25:  Culling frequency by treatment from cows supplemented with conjugated linoleic acid 
(CLA).  Control (Con) fed cows received no CLA supplementation, CLA-fed cows were supplemented 
with either 150 g/h/d or 75 g/h/d of Lutrell® post-partum. Treatment initiation began 21 d prior to 
calving and ceased 15 DIM ± 3 d. Values represent LS means for the control and CLA 
supplementation. 
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CHAPTER 3 
 
The Effects of Organic Zinc Supplementation on Production and Metabolism in 
Lactating Holstein Cows 
 
ABSTRACT 
Multiparous (n=66) and primiparous (n=41) Holstein cows were blocked by  
previous 305 d mature equivalent milk yield and parity and assigned to 1 of 3 dietary 
treatments:  1) 75 mg/kg DM supplemental Zn provided entirely as Zn sulfate 
(control [Con]), 2) the control diet except 33.3 mg/kg DM Zn sulfate in the close up 
and 15.5 mg/kg DM of Zn sulfate in the lactation diet was replaced by a Zn amino 
acid complex from Availa®Zn (Med), and 3) the control diet except 66.6 mg/kg DM 
Zn sulfate in the close up and 40.0 mg/kg DM of Zn sulfate in the lactation diet was 
replaced by Zn amino acid complex from Availa®Zn (High).  Cows were housed at 
the Iowa State University Dairy farm, and were individually delivered a TMR 
containing dietary treatments beginning at 28 ± 15 d prior to expected calving date 
and ceased at 56 DIM.  Feeding increasing levels of OZ increased colostrum IgG 
levels in multiparous and increased milk lactose percentage of heifers, but OZ 
treatment had no overall effect on milk yield, component corrected milk yield, DMI, 
calculated feed efficiency, milk components, milk somatic cell linear score or plasma 
energetic metabolites.  Irrespective of treatment, cows that experienced ketosis or 
metritis had an increase in plasma LPSBP concentration.  It appears that increasing 
the levels of dietary OZ had little effect on production variables during the transition 
period.      
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INTRODUCTION 
Early lactation cows are typically unable to consume adequate dietary energy to 
meet requirements for milk production and maintenance, and consequently enter 
into a state of calculated net NEBAL.  Negative energy balance is associated with 
poor immune system status of the transition cow (Goff, 2006). Trace minerals play 
key roles in immune function (Miller et al., 1988) and supplementing organic trace 
minerals (OTM) has been demonstrated to have positive responses in lactating dairy 
cattle. For example, supplementing OTM has been shown to reduce SCC, increase 
milk production, improve reproductive performance, and improve hoof health 
(Uchida et al., 2001; Nocek et al., 2006).  
 Of all the minerals, Zn plays a particularly key role in immune function.  
Studies in humans and animals demonstrate decreased natural killer cell activity 
during periods of Zn deficiency (Fernandes, 1979; Allen et al., 1983).   B-lymphocyte 
antibody responsiveness is inhibited by Zn deficiency (Fraker et al., 1978; Luecke et 
al., 1978; DePasquale-Jardieu et al., 1984). Monocytes from Zn deficient mice had 
impaired killing of intracellular parasites, which was rapidly corrected in vitro by 
addition of Zn (Wirth et al., 1989).  Furthermore, Zn deficient animals exhibit 
increased spontaneous and toxin-induced apoptosis in multiple cell types (Dinsdale 
and Williams, 1977; Zalewski and Forbes, 1993).  Additionally, in human subjects, 
Zn supplementation has been identified as powerful immune system booster, with 
efficacy dependent upon dose (Fraker et al., 2000). 
 A number of studies have demonstrated the benefits of feeding OTM in 
lactating dairy cattle, however fewer studies have specifically examined the effects 
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of Availa®Zn supplementation.  Study objective were to investigate whether OZ 
supplementation during the transition period improves production and metabolic 
parameters of transitioning dairy cows.  
 
MATERIALS AND METHODS 
 The Iowa State University Institutional Animal Care and Use Committee 
approved all procedures involving animals.  Multiparous (n=66) and primiparous 
(n=41) Holstein cows were blocked by previous 305mature equivalent milk yield and 
parity and assigned to 1 of 3 dietary Zn treatments beginning 28 ± 15 d prior to 
expected calving and ceased at 56 DIM (Figure 3.1).  Treatments were: 1) 75 mg/kg 
of DM supplemental Zn provided entirely as Zn sulfate (Con), 2) the control diet 
except 33.3 mg/kg of DM of  Zn sulfate in the close up and 15.5 mg/kg of DM of Zn 
sulfate in the lactation diet were replaced by a Zn amino acid complex from 
Availa®Zn (Med), and 3) the control diet except 66.6 mg/kg DM of Zn sulfate in the 
close up and 40.0 mg/kg of DM of Zn sulfate in the lactation diet was replaced by Zn 
amino acid complex from Availa®Zn (High).  Inorganic zinc, manganese, copper and 
cobalt were provided as sulfate sources.  All treatments received 25 mg/d of 
dihydroiodide ethanediamine (EDDI) with the remaining supplemental iodine proved 
as potassium iodide.  Supplemental selenium was supplied as sodium selenite 
across all treatments.  Supplemental iron was provided from various inorganic 
sources and did not exceed 10 mg/kg.  Cows were housed at the Iowa State 
University Dairy and were individually fed a TMR formulated by Dairy Health 
Services (Sanborn, IA) to meet or exceed the predicted requirements (NRC, 2001) 
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of energy, protein, minerals and vitamins.  Corn silage was the main forage source 
and ground corn was the primary concentrate (Table 3.2 and 3.3).  The TMR was 
sampled weekly, composited monthly, and analyzed by wet chemistry methods 
(Dairyland Lab Services, Arcadia, WI).  The diets were formulated to be isoenergetic 
as well as isonitrogenous and meet all NRC recommmendations.  The vitamin pack 
was formulated to meet or exceed NRC recommendations for trace minerals and 
vitamins with the only difference being the ratio of inorganic to OZ, respective of 
treatment (Table 3.4). 
Cows were individually fed (using the Calan Broadbent feeding system; 
American Calan, Northwood, NH) ad libitum portions of fresh feed daily at 0800 and 
1700 h; orts were weighed and recorded daily at 0700 h for lactating cows.  Cows in 
the “close up” pens were delivered fresh feed at 1100 h with individual orts collected 
and weighed at 1000 h.  Immediately post-calving, cows were moved to a maternity 
barn where they were milked and a colostrum sample was obtained.   Cows also 
received a 300cc oral drench of propylene glycol and a calcium gel (Jorgenson 
Labs, Loveland, Colorado). Following the initial milking, cows were moved into a 
“prep” pen in the lactation barn for a minimum of two milkings, until they passed a 
California Mastitis Test (CMT) after which they were then moved into an 
experimental pen and trained to appropriate Calan door. Cows were milked twice 
daily at 0730 and 1800 h and yield was recorded and condensed by week for 
statistical analysis.  Milk samples for composition analyses were obtained weekly 
from each cow began at d 7 and ended at 56 ± 3 d.  The sample was stored at 4°C 
with a preservative (bronopol tablet; DandF Control System, San Ramon, CA) until 
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analysis by Dairy Lab Services (Dubuque IA) using AOAC approved infrared 
analysis equipment and procedures for milk components.  Blood samples and rectal 
temperatures were obtained from all cows on d -21, -7, 3, 7, 10, 14, 21, 28, and 56 ± 
1 DIM relative to calving.  Blood samples were collected via coccygeal venipuncture 
using sodium heparin vacutainers (BD Vacutainer Ref 366480; Franklin Lakes, NJ).  
Blood samples from lactating cows were obtained at 1000 h, and blood samples 
from prefresh cows were collected at 0900 h.  Blood samples were kept on ice until 
centrifuged at 2100 x g for 15 min.  Plasma was split into two aliquots and frozen at -
20°C until analysis.   
Plasma NEFA, BHBA and glucose concentrations were determined 
enzymatically using commercially available kits validated for use in our laboratory 
(NEFA C kit; Wako Chemicals USA, Richmond VA; Autokit Glucose C2; Wako 
Chemicals USA, Inc.).  These procedures were scaled down and conducted in 96-
well microplates (Rainin Instrument, LLC, Oakland, CA) and read using a microplate 
photometer (SpectraMax Plus, Molecular Devices, Silicon Valley, California).  The 
inter- and intra-assay coefficients for the BHBA, NEFA and glucose assay were 
10.6, 5.8, 10.8, 6.4, 10.0 and 2.6%, respectively.   
A subset of cows (n=16) were selected for retrospective lipopolysaccharide 
binding protein (LPSPB) analysis based on transition period success.  Animals 
selected were defined as cows that transitioned “well” or cows that transitioned 
“poorly”.  Poor transition cows (n=7) were defined as cows that were diagnosed and 
treated for ketosis or metritis within 22 d after parturition (Table 3.5).  Cows defined 
as transitioning well (n=9) did not experience ketosis, metritis, LDA, mastitis or RP 
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during the transition period. Blood samples included in analysis were from time 
points d -21, 3, 10, 21 and 56 ± 1 relative to calving.  Samples were kept on ice until 
centrifuged at 2100 x g for 15 min.  Plasma was split into two aliquots, frozen at -
20°C and later analyzed.  Plasma concentration of LPSBP was determined 
enzymatically using a commercially available kit (LBP for a wide variety of species 
HK503; Hycult biotech, Plymouth Meeting, PA).  Prior to analysis, samples were 
diluted 1:900 in assay buffer.  Additionally, daily observations and general health 
records were recorded throughout the study. 
Colostrum Sampling and Analysis 
Colostrum samples were obtained from cows at the first milking after 
parturition and analyzed for IgG content.  To prevent calves from nursing, the calf 
was removed from the dam immediately after parturition.  Upon sample collection, 
samples were immediately frozen at -20°C and retained until all samples had been 
collected.  Colostrum IgG analysis was conducted by Global Beta Health (Ames, IA).  
Prior to assay, samples were diluted 1:1000 in assay buffer.  Colostrum IgG 
concentration was determined using radial immunodiffusion assay (Triple J Farms, 
Bellingham, WA). 
Water Analysis 
 Water from the ISU dairy was sampled one week prior to trial start date to test 
for trace mineral content and overall water hardness (Table 3.1).  A fresh water 
sample was obtained directly from the tap after allowing water to run for four 
continuous minutes.  Water samples were collected in the same fashion from tanks 
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in both the prefresh and lactating barn at the Iowa State University Dairy Farm.   
Water analysis was conducted by Dairyland Labratories, Inc. (Arcadia, WI).   
Calculations 
Fat corrected milk (FCM) and solids corrected milk (SCM) were calculated 
(NRC, 2001) using the following equations: 3.5% FCM = (0.432 x milk yield) + (16.23 
x milk fat yield); SCM = (0.327 x milk yield) + (12.95 x milk fat yield) + (7.2 x milk 
protein yield). 
Statistical Analysis 
  Milk yield, 3.5% FCM, 4.0% SCM, DMI, FE, body temperature, plasma NEFA, 
BHBA, glucose and LPSBP were analyzed by repeated measures using the PROC 
MIXED procedure of SAS (2005) with an autoregressive covariance structure and 
week of lactation as the repeated affect.  The model contained week of lactation, 
treatment, parity and week of lactation x treatment interactions.  Cows were the 
random effect and week of lactation, treatment and week of lactation x treatment 
interaction were the fixed effects.  Health events and colostrum IgG were measured 
using the ANOVA procedure of SAS.  Milk components were analyzed by repeated 
measures using the PROC MIXED procedure of SAS (2005) with an autoregressive 
covariance structure and day of lactation as the repeated effect. The model 
contained day of lactation, treatment, parity and day x treatment interactions.  Cows 
were the random effect, and day of lactation, treatment, parity and week of lactation 
x treatment interaction were the fixed effects. Standard errors of the mean are 
reported and differences considered significant when P < 0.05 unless otherwise 
stated.  
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RESULTS 
Overall milk yield (Figure 3.2; 38.5 kg/d), 3.5% FCM (Figure 3.3; 44.3 kg/d), 
4.0% SCM (Figure 3.4; 39.3 kg/d) and calculated feed efficiencies (Figures 3.5; 3.6; 
3.7) were not affected (P > 0.10) by OZ supplementation (Table 3.6).  However, 
Med-fed multiparous cows had reduced milk yield at weeks 1-7 of lactation when 
compared to both the Con and the High OZ supplemented cows (Figure 3.2), there 
was a treatment x time interaction on DMI, which demonstrated Med-fed cows had 
reduced DMI during weeks 1-6 (Figure 3.8; P < 0.01). A reduction in component 
corrected milk (3.5% FCM weeks 1 and 4 and 4.0% SCM weeks 4 through 7) was 
observed for Med-fed cows (Table 3.6, Figures 3.3 and 3.4).  There was a treatment 
x DIM effect on milk fat and protein components (Table 3.6; Figures 3.9 and 3.10; P 
< 0.01 and P = 0.02, respectively;).  Milk fat percentage was greater for Con-fed 
animals, irrespective of parity, during the first week of lactation (17.5%; P < 0.01), 
but no treatment differences in milk fat were observed for the remainder of the 
experiment.  Similar to milk fat, milk protein percentage was reduced during week 
one for the High-fed cows (Figure 3.10), but no differences in milk protein 
percentage (P < 0.10) were observed for the remainder of the experiment.       
There was a treatment by parity interaction on milk lactose percentage 
(Figure 3.11), and MUN levels (Figure 3.11), colostrum IgG concentration (Figure 
3.12).  Heifers fed Med and High OZ had increased milk lactose (2.9%) compared to 
Con-fed heifers throughout the treatment period (Figure 3.11).  Milk urea nitrogen 
levels were increased in Med and High OZ supplemented multiparous animals but 
not heifers (Figure 3.11).  Colostrum IgG concentration was increased by OZ 
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treatment (20.3%) in multiparous cows but not in heifers, but there were no 
differences between the Med and High OZ supplemented groups (Figure 3.12).  
There was no overall treatement effect of OZ supplementation on milk lactose 
percentage, MUN percentage or SCCLN in early lactation (Figures 3.13: 3.14; 3.15; 
P < 0.10).  
There were no treatment effects on plasma glucose concentrations (72.5 
mg/dL), NEFA (469.3 mEq/L), or BHBA (7.4 mg/dL; Table 3.7; Figure 3.16; 3.17; 
3.18).  Additionally, there appeared to be little to no effect on rectal temperature 
(Figure 3.19).There was no treatment effect on measured health parameters 
including DA (6%), ketosis (8%), mastitis (7.6%) or metritis (6%; Table 3.8; Figure 
3.20).   
Due to the limited number of health events resulting in a cull, statistical 
analysis was not conducted on culling and not reported herein.     
Animals classified as “Poor” transition cows had increased (P = 0.04) 
circulating LPSBP concentration (~21%, Figure 3.21, Table 3.9).  Furthermore a 
treatment x DIM interaction was observed with regard to circulating LPSBP 
concentration, was two-fold greater at three DIM and remaining elevated at 10 DIM 
(P < 0.01; Figure 3.21). 
  
DISCUSSION 
During the periparturient period the dairy cow must undergo a series of well-
orchestrated transitions through physiological states mediated by several substantial 
and coordinated metabolic adaptations to meet the demands for galactopoesis and 
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ultimately copious production.  At this time, the dairy cow’s physical capacity for feed 
intake is inadequate to meet the necessary demands for milk production, and she 
consequently enters NEBAL. Negative energy balance is associated with (and 
maybe the cause of) the poor immune system status of the transition cow (Goff, 
2006).  Trace minerals, specifically Zn, play key roles in immune function (Miller et 
al., 1988). Zinc is a biologically essential element required for cell growth, 
development, differentiation, homeostasis, connective tissue growth and 
maintenance, DNA synthesis, RNA transcription, cell division and cell activation 
(Chasapis et al., 2011).  
The degree to which Zn status is believed to effect lactational performance 
has increased in accordance with the scientific understanding of its biological role.  
In support of this, the NRC has increased the recommended dietary Zn levels for 
lactating dairy cows in its last two publications (NRC 1989, 2001).  However, the bio-
availability of trace minerals can be hindered by a variety of factors including dietary 
antagonists, animal age, etc.  Minerals have traditionally been supplied in an 
inorganic form (i.e. sulfate or oxide), but organic chelation of minerals to amino acid 
complexes improves its bioavailability (Wedekind et al., 1992).   Further OTM have 
greater retention in the body compared to inorganic mineral sources (Nockels et al., 
1993).  In addition, supplementing OTM has been shown to positively influence 
lactational parameters in some experiments (Rabiee et al., 2010).  However, there is 
a general lack of understanding by which OZ mechanistically improves milk yield.  
Our hypothesis was that a mixture of inorganic and OZ above NRC (2001) 
recommended dietary levels would have positive production responses in 
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periparturient dairy cattle mediated by improved functionality or efficacy of the 
immune system resulting in a decrease in the energy requirement for maintenance.  
Improved EBAL status could theoretically improve production response(s). 
Moreover, very little is known about how, or if, feeding supplemental Zn affects blood 
bioenergetic parameters (NEFA, glucose, insulin, etc.) and this was of interest in 
determining Zn’s role in nutrient metabolism of early lactation dairy cows. 
Several studies indicate that OZ supplementation reduces milk SCC 
(Wealsby et al., 1985; Salema et al., 2001; Cope et al., 2003, Schobhanirad et al., 
2010).  Zinc is required for the maintenance of skin integrity, stabilization of cell 
membranes, and activation of the immune system (Miller and Madsen, 1992).  It 
seems plausible that improved Zn availability could improve immune system function 
and/or improve teat and mammary epithelial health.  Zinc plays a role in keratin plug 
formation in the teat canal, and this is thought to be one reason for why OZ reduces 
the incidence of mastitis (Spain, 1993).  However, in the current experiment, milk 
SCCLN and the incidence of mastitis did not differ.  Therefore, either we did not 
utilize enough animals to detect difference or the immune system and the mammary 
gland apparently did not benefit from increased dietary OZ supplementation.          
Given our proposed hypothesis regarding mode of action, and the 
aforementioned unaffected SCCLN it seems logical that OZ supplementation had no 
effect on milk yield.  The effect of OZ is variable but some reports indicate OZ 
increased milk yield (Cope et al., 2003; Schwimmer and Braun, 2001; Kellogg et al., 
1989; Aguilar et al., 1988b; Kincaid et al., 1985; Wealsby et al., 1985). To our 
knowledge, no experiments have assessed the effects of OZ supplementation on 
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feed intake and feed efficiency in periparturient dairy cows.  In the current study we 
observed calculated feed efficiency to be unaffected by OZ supplementation.  . 
Overall, milk fat percentage was not altered by treatment in our study which is 
contrary to the findings reported by a limited a number of trials which have 
suggested OZ positively effects milk fat (Kellogg et al., 1989; Schwimmer and Braun, 
2001; Cope et al., 2003).  Furthermore, we observed no overall response to 
treatment with regard to milk protein or lactose percentage, however OZ 
supplemented heifers had significantly increased milk lactose than multiparous 
cows, which could indicate improved glucose sparing mechanisms in OZ-
supplement primiparous animals. Effects of OZ supplementation on milk lactose had 
only been demonstrated one other time, by Wealsby and coworkers (1985) and they 
too observed an increased in milk lactose percentage.  
Plasma NEFA, BHBA, and glucose were measured in an effort to determine if 
OZ had effect on tissue catabolism and metabolism.  In the present study no 
difference were observed for NEFA, BHBA or glucose.  We are unaware of research 
that evaluated plasma energetic variables in conjunction with OZ supplementation 
through the periparturient period 
Recorded health parameters were unaffected by OZ supplementation. Prior to 
the present study, the incidence of health events were previously not emphasized in 
the OZ lactation literature, which is surprising given Zn’s reputation as being vital to 
immune function.  The lack of reduction in health events could again be attributed to 
the lack of improvement to EBAL status (not calculated), or this could be due to the 
loose association between metabolic disorders and NEBAL.  It is possible that EBAL 
92 
status has little effect on health parameters, suggesting that an increase in immune 
system activity, and overall system immune function, would be inadequate to 
overcome metabolic disorders and consequently impact health or culling events.    
Due to a lack of observed production differences coupled with apparently 
minimal effect on post-partum immune system activity it is likely that OZ had no 
effect on EBAL and this is exemplified by no change in calculated feed efficiency.  
Although results vary, OZ has been shown to have beneficial effects regarding 
lactation performance (Wealsby et al., 1985; Cope et al., 2003).  This could be a 
possible indication of varying initial Zn status or perhaps heightened effects limiting 
availability such as hard water, cow age or dietary antagonists. 
Assessing Zn status, though challenging, becomes important as Zn dietary 
deficiencies result in decreased growth, milk production, feed efficiency, immune 
function, and reproduction.  Without knowledge or ability to accurately measure Zn 
status it is difficult to attribute positive production responses to increased Zn 
supplementation above minimum requirements or simply a return to required Zn 
supplementation rate.  
Our study did demonstrate significant results with regard to endogenous 
endoxin levels amongst transition cows.  Irregardless of OZ treatment, we evaluated 
a small subset of animals that transitioned “good” or “poorly”.  Studies have 
demonstrated an association between elevated LPSBP levels and frequency of 
metabolic disorders (Bannerman et al., 2003; Zebeli et al., 2009) however in these 
experiments endotoxemia was induced (via LPS infusion).  Our results confirm that 
cows that transition “poorly” had twice as much plasma LPSBP as those that 
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transitioned “well”.  As far as we know, this is the first time LPSBP has been 
evaluated in transition cows that were not on an endotoxemia induced treatment.  
The observed increase in postpartum LPSBP levels could originate from a variety of 
places such as the damaged uterus or the insulted GI tract.  We believe that some 
cows are more susceptible to endotoxemia resulting from the rapid change from a 
low to a high concentrate diet immediately post-partum.  Moreover, this increased 
sensitivity is partially responsible for the occurrence or exacerbation of metabolic 
disorders.  Further research is necessary to categorize the temporal pattern of 
endotoxin levels in poor transition cows, and secondly, determine what is causing 
elevated endotoxin levels (leaky gut, uterine involution, environmental stress, etc.). 
CONCLUSION 
This present study demonstrates that supplementing cows with OZ failed to 
improve milk yield, feed efficiency, or energetic parameters.  Multiparous cows and 
primiparous cows differed in their response to the product with regard to colostrum 
IgG concentration and milk lactose percentage.  Further research is required to 
determine the effects of OZ supplementation on gut integrity.  Moreover, additional 
research evaluating the Zn status of periparturient dairy cows is necessary to 
determine if feeding a mixture of inorganic and organic forms of Zn would be 
sufficient to generate positive response(s). 
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Table 3.1:  Iowa State Dairy farm water analysis1. 
 Pre-fresh Barn 
(ppm) 
Lactating Barn 
(ppm) 
Nitrite 5.21 5.08 
pH 7.71 8.70 
Calcium 38.040 34.900 
Magnesium 18.540 18.190 
Phosphorous 1.636 0.248 
Potassium 2.969 2.390 
Copper 0.015 <0.001 
Iron 0.062 0.034 
Zinc 0.138 0.015 
Sodium 12.190 11.730 
Manganese  0.011 0.003 
Chloride 33.00 27.000 
Sulfates 57.420 56.790 
Total Dissolved 260.000 255.000 
Water Hardness 171 162 
1Livestock water analysis conducted by Dairyland Laboratories, Inc. (Arcadia, 
WI). 
Figure 3.1:  Experimental protocol schematic.   
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Table 3.2:  Ingredient formulation of the diet. 
Item      Prefresh    Lactation 
Ingredient, % DM   
Alfalfa hay 18.3 10.2 
Oat straw 27.1 - 
Corn silage 38.5 47.1 
Corn grain, ground 4.6 8.6 
Whole cottonseed - 9.0 
Soybean hulls - 8.9 
Soybean meal, 48% - 6.1 
Soybean meal, 44% 7.0 - 
Amino-Plus2 - 5.1 
Fish meal, menhaden - 1.12 
Limestone 0.51 0.78 
Animal fat - 0.64 
Magnesium sulfate 0.80 0.58 
Urea - 0.58 
Sodium bicarbonate - 0.53 
Ammonium chloride 0.51 - 
Salt 0.25 0.43 
Blood meal 1.22 - 
Dicalcium phosphate - 0.20 
Selenium 200 0.08 - 
Diamond V XP yeast3 0.51 - 
Vitamin E 0.42 - 
Vitamin/mineral pack 0.17 0.14 
Rumensin 804 0.011 0.005 
1 The prepartum diet was fed for approximately 28 d.  The lactation ration was fed 
from 1 to 56 DIM. 
2 Amino-Plus heat-treated soybean meal (Ag Processing, Inc., Omaha, NE). 
3 Diamond V XP yeast fermentation metabolites of Saccharomyces cerevisiae 
(Diamond V Mills, Cedar Rapids, IA). 
4 Rumensin 80, monensin mono-sodium salt (Elanco Animal Health, Greenfield, 
IN). 
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Table 3.3:  Dietary composition of the formulated prefresh and lactation 
rations. 
Nutrient Prefresh Lactation 
CP, % 13.9 17.6 
NEL, mcal/kg 1.41 1.68 
ADF, % 29.2 23.9 
NDF, % 42.8 35.3 
NFC, % 33.1 35.4 
Starch, % 19.4 23.8 
Fat, % 2.6 5.1 
Ash, % 8.4 7.4 
Ca, % 0.75 0.78 
P, % 0.22 0.39 
Mg, % 0.39 0.37 
K, % 1.59 1.22 
Na, % 0.26 0.35 
Cl, % 0.87 0.46 
S, % 0.30 0.26 
Vitamin A, KIU/kg 11.10 9.12 
Vitamin D, KIU/kg 3.35 2.76 
Vitamin E, IU, kg 212.34 25.40 
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Table 3.4:  Ingredient formulation of vitamin pack. 
 Control Medium Zinc High Zinc 
 Inorganic Complexes
 
Inorganic Complexes
 
Inorganic Complexes
 
Close-up
1
 (mg/kg)       
    Zn 75.0 0 41.7 33.3 8.4 66.6 
    Mn 41.5 18.5 41.5 18.5 41.5 18.5 
    Cu 3.4 11.6 3.4 11.6 3.4 11.6 
    Co 0 1.11 0 1.11 0 1.11 
    Fe <10 0 <10 0 <10 0 
    I 0.9 0 0.9 0 0.9 0 
   Se 0.3 0 0.3 0 0.3 0 
Lactation
2
 (mg/kg)       
    Zn 75.0 0 59.5 15.5 35.0 40.0 
    Mn 51.4 8.6 51.4 8.6 51.4 8.6 
    Cu 9.6 5.4 9.6 5.4 9.6 5.4 
    Co 0 1.08 0 1.08 0 1.08 
    Fe <10 0 <10 0 <10 0 
    I    0.9 0 0.9 0 0.9 0 
   Se 0.3 0 0.3 0 0.3 0 
1
Estimated using a dry matter intake of 10.6 kg/d during the 21-d close-up phase. 
2
Estimated using a dry matter intake of 23.2 kg/d from 1-56 DIM phase. 
   
Table 3.5:  Subset of poor transition cows (n=7) that were selected for LPSBP 
1Cow Disorder DIM at Disorder 
1 Ketosis 1 
2 Ketosis 7 
3 Ketosis 14 
4 Ketosis 11 
5 Ketosis 8 
5 Metritis 8 
6 Ketosis 7 
7 Metritis 22 
1Cows were retrospectively selected for analysis following diagnosis with metabolic 
disorder. 
 
98 
Table 3.6:  Effect of supplementing organic zinc on production parameters, dry matter intake and feed efficiency1 
 Treatment2  P 
Parameter Con Med High SEM    TRT TRT x WOL 
TRT x  
WOL x Par 
Milk Yield, kg/d 39.12 37.35 39.14 0.87 0.21 0.66 0.79 
Dry Matter Intake, kg 16.48 15.55 16.20 0.32 0.11 0.97 0.96 
Rectal Temperature 38.31 38.25 38.32 0.03 0.24 0.01 0.04 
3.5% FCM3, kg/d 45.19 42.94 44.75 1.15 0.33 0.08 0.39 
4.0% SCM4, kg/d 40.05 38.20 39.74 0.99 0.36 0.09 0.31 
Milk Composition        
Fat, % 4.61  4.44  4.42 0.09 0.30 <0.01 0.09 
Protein, % 2.94 2.95 2.93 0.03 0.90 0.02 0.60 
Lactose, % 4.83 4.85 4.83 0.02 0.76 0.16 0.84 
MUN5, % 13.23 13.59 13.67 0.03 0.91 0.50 0.03 
SCCLN6 1.73 1.78 1.82 0.05 0.58 0.34 0.03 
Colostrum IgG, 
mg/ml 
87.54 92.18 98.07 5.29 0.33 - 0.02 
Feed Efficiency        
MY/DMI  2.14 2.21  2.23 0.36 0.63 0.83 0.30 
FCM/DMI 2.43 2.43 2.47 0.06 0.89 0.32 0.18 
SCM/DMI 2.15 2.16 2.19 0.05 0.87 0.46 0.25 
1Average over the 56 d post-partum period 
2Treatments were Zn Sulfate (Con); 33.3 mg/kg Zn amino acid complex from Availa®Zn (Med); 66.6 mg/d 
Zn sulfate in the close up and 40.0 mg/kg of Zn sulfate in the lactation diet was replaced by Availa®Zn 
(High)  
3Fat Corrected Milk = (0.432 x milk yield) + (16.23 x milk fat yield) 
4Solids Corrected Milk = (12.24 x milk fat yield) + (7.1 x milk protein yield) + (6.35 x milk lactose yield) – 
(0.0345 x milk yield) 
5Milk Urea Nitrogen 
6Somatic Cell Count Linear Score 
a,b Values within rows with differing superscripts indicate P < 0.05 
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Table 3.7:  Effect of zinc source on plasma metabolites. 
 Treatment  P 
Parameter Con Med High SEM TRT DIM TRT x DIM Parity 
Glucose, mg/dL 72.5 73.0 72.2 0.5 0.8 <0.01 0.5 <0.01 
NEFA1, mEq/L 456.8 482.2 468.9 21.2 0.7 <0.01 0.6 0.60 
BHBA2, mg/dL 7.3 7.6 7.4 0.3 0.7 <0.01 0.8 0.01 
1Nonesterified Fatty Acids 
2β-hydroxybutyrtic acid   
  
Table 3.8:  Effect of zinc source on health events. 
 Treatment   P 
Parameter Con Med High SEM TRT Parity TRT x Parity 
Displaced abomasum, % (#) 3 (1) 7 (3) 8 (3) 0.06 0.28 0.69 0.26 
Ketosis, % (#) 6 (2) 5 (2) 13 (5) 0.04 0.54 0.79 0.43 
Mastitis, % (#) 3 (1) 7 (3) 13 (5) 0.04 0.28 0.28 0.61 
Metritis, % (#) 3 (1) 7 (3) 8 (3) 0.04 0.57 0.91 0.50 
Retained Placenta, % (#) -    2 (1) -   0.04    0.64 - - 
Table 3.9:  Endogenous LPSBP production in periparturient cows with treatment based upon transition period 
success. 
 Treatment  P 
Parameter “Good” “Poor” SEM TRT DIM TRT x DIM 
LPSBP, ng/L 14017 17878 1249 0.04 <0.01 <0.01 
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Figure 3.2:  Temporal pattern of early lactation milk yield by parity (A) and treatment 
(B) from cows supplemented with organic zinc (OZ).  Control (Con) fed cows 
received no OZ supplementation, Medium (Med) cows were supplemented 15.5 
mg/kg of DM with Availa®Zn post-partum and High (High) cows were supplemented 
40 mg/kg/ of DM with Availa®Zn post-partum. Treatment initiation occurred 28 ± 15 
d prior to calving and ceased at 56 DIM. Values represent LS means for the Con, 
Med, and High Availa®Zn supplementation.  
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Figure 3.3:  Temporal pattern of early lactation 3.5% FCM by parity (A) and 
treatment (B) from cows supplemented with organic zinc (OZ).  Control (Con) fed 
cows received no OZ supplementation, Medium (Med) cows were supplemented 
15.5 mg/kg of DM with Availa®Zn post-partum and High (High) cows were 
supplemented 40 mg/kg/ of DM with Availa®Zn post-partum. Treatment initiation 
occurred 28 ± 15 d prior to calving and ceased at 56 DIM. Values represent LS 
means for the Con, Med, and High Availa®Zn supplementation.   
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Figure 3.4:  Temporal pattern of early lactation 4.0% SCM milk yield by parity (A) 
and treatment (B) from cows supplemented with organic zinc (OZ).  Control (Con) 
fed cows received no OZ supplementation, Medium (Med) cows were supplemented 
15.5 mg/kg of DM with Availa®Zn post-partum and High (High) cows were 
supplemented 40 mg/kg/ of DM with Availa®Zn post-partum. Treatment initiation 
occurred 28 ± 15 d prior to calving and ceased at 56 DIM. Values represent LS 
means for the Con, Med, and High Availa®Zn supplementation. 
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Figure 3.5:  Temporal pattern of early lactation feed efficiency calculated as MY/DMI 
for parity (A) and treatment (B) from cows supplemented with organic zinc (OZ).  
Control (Con) fed cows received no OZ supplementation, Medium (Med) cows were 
supplemented 15.5 mg/kg of DM with Availa®Zn post-partum and High (High) cows 
were supplemented 40 mg/kg/ of DM with Availa®Zn post-partum. Treatment 
initiation occurred 28 ± 15 d prior to calving and ceased at 56 DIM. Values represent 
LS means for the Con, Med, and High Availa®Zn supplementation.   
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Figure 3.6:  Temporal pattern of early lactation feed efficiency calculated as 3.5% 
FCM/DMI for parity (A) and treatment (B) from cows supplemented with organic zinc 
(OZ).  Control (Con) fed cows received no OZ supplementation, Medium (Med) cows 
were supplemented 15.5 mg/kg of DM with Availa®Zn post-partum and High (High) 
cows were supplemented 40 mg/kg/ of DM with Availa®Zn post-partum. Treatment 
initiation occurred 28 ± 15 d prior to calving and ceased at 56 DIM. Values represent 
LS means for the Con, Med, and High Availa®Zn supplementation.  
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Figure 3.7:  Temporal pattern of early lactation feed efficiency calculated as 4.0% 
SCM/DMI for parity (A) and treatment (B) from cows supplemented with organic zinc 
(OZ).  Control (Con) fed cows received no OZ supplementation, Medium (Med) cows 
were supplemented 15.5 mg/kg of DM with Availa®Zn post-partum and High (High) 
cows were supplemented 40 mg/kg/ of DM with Availa®Zn post-partum. Treatment 
initiation occurred 28 ± 15 d prior to calving and ceased at 56 DIM. Values represent 
LS means for the Con, Med, and High Availa®Zn supplementation.  
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Figure 3.8:  Temporal pattern of DMI relative to parturition by parity (A) and 
treatment (B) from cows supplemented with organic zinc (OZ).  Control (Con) fed 
cows received no OZ supplementation, Medium (Med) cows were supplemented 
15.5 mg/kg of DM with Availa®Zn post-partum and High (High) cows were 
supplemented 40 mg/kg/ of DM with Availa®Zn post-partum. Treatment initiation 
occurred 28 ± 15 d prior to calving and ceased at 56 DIM. Values represent LS 
means for the Con, Med, and High Availa®Zn supplementation.  
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Figure 3.9:  Temporal pattern of early lactation milk fat percentage by parity (A) and 
treatment (B) from cows supplemented with organic zinc (OZ).  Control (Con) fed 
cows received no OZ supplementation, Medium (Med) cows were supplemented 
15.5 mg/kg of DM with Availa®Zn post-partum and High (High) cows were 
supplemented 40 mg/kg/ of DM with Availa®Zn post-partum. Treatment initiation 
occurred 28 ± 15 d prior to calving and ceased at 56 DIM. Values represent LS 
means for the Con, Med, and High Availa®Zn supplementation.   
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Figure 3.10:  Temporal pattern of early lactation milk protein percentage by parity 
(A) and treatment (B) from cows supplemented with organic zinc (OZ).  Control 
(Con) fed cows received no OZ supplementation, Medium (Med) cows were 
supplemented 15.5 mg/kg of DM with Availa®Zn post-partum and High (High) cows 
were supplemented 40 mg/kg/ of DM with Availa®Zn post-partum. Treatment 
initiation occurred 28 ± 15 d prior to calving and ceased at 56 DIM. Values represent 
LS means for the Con, Med, and High Availa®Zn supplementation.  
2.25 
2.5 
2.75 
3 
3.25 
3.5 
3.75 
4 
1 2 3 4 5 6 7 8 
M
il
k
 P
ro
te
in
 (
%
) 
Weeks of Lactation 
Con Parity 1 
Med Parity 1 
High Parity 1 
Con Parity 2 
Med Parity 2 
High Parity 2 
B 
A 
109 
 
 
 
Figure 3.11:  Temporal pattern of milk lactose (A) and MUN (B) percentage 
treatment x parity interaction from cows supplemented with organic zinc (OZ).  
Control (Con) fed cows received no OZ supplementation, Medium (Med) cows were 
supplemented 15.5 mg/kg of DM with Availa®Zn post-partum and High (High) cows 
were supplemented 40 mg/kg/ of DM with Availa®Zn post-partum. Treatment 
initiation occurred 28 ± 15 d prior to calving and ceased at 56 DIM. Values represent 
LS means for the Con, Med, and High Availa®Zn supplementation.   
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Figure 3.12:  The interaction between OZ treatment x parity and its effects on 
colostrum IgG results (A) and treatment effects on IgG (B) from cows supplemented 
with organic zinc (OZ).  Control (Con) fed cows received no OZ supplementation, 
Medium (Med) cows were supplemented 15.5 mg/kg of DM with Availa®Zn post-
partum and High (High) cows were supplemented 40 mg/kg/ of DM with Availa®Zn 
post-partum. Treatment initiation occurred 28 ± 15 d prior to calving and ceased at 
56 DIM. Values represent LS means for the Con, Med, and High Availa®Zn 
supplementation.  
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Figure 3.13:  Temporal pattern of early lactation milk lactose percentage by parity 
(A) and treatment (B) from cows supplemented with organic zinc (OZ).  Control 
(Con) fed cows received no OZ supplementation, Medium (Med) cows were 
supplemented 15.5 mg/kg of DM with Availa®Zn post-partum and High (High) cows 
were supplemented 40 mg/kg/ of DM with Availa®Zn post-partum. Treatment 
initiation occurred 28 ± 15 d prior to calving and ceased at 56 DIM. Values represent 
LS means for the Con, Med, and High Availa®Zn supplementation.  
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Figure 3.14:  Temporal pattern of early lactation milk MUN by parity (A) and 
treatment (B) from cows supplemented with organic zinc (OZ).  Control (Con) fed 
cows received no OZ supplementation, Medium (Med) cows were supplemented 
15.5 mg/kg of DM with Availa®Zn post-partum and High (High) cows were 
supplemented 40 mg/kg/ of DM with Availa®Zn post-partum. Treatment initiation 
occurred 28 ± 15 d prior to calving and ceased at 56 DIM. Values represent LS 
means for the Con, Med, and High Availa®Zn supplementation.  
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Figure 3.15:  Temporal pattern of early lactation somatic cell count linear number 
(SCCLN) by parity (A) and treatment (B) from cows supplemented with organic zinc 
(OZ).  Control (Con) fed cows received no OZ supplementation, Medium (Med) cows 
were supplemented 15.5 mg/kg of DM with Availa®Zn post-partum and High (High) 
cows were supplemented 40 mg/kg/ of DM with Availa®Zn post-partum. Treatment 
initiation occurred 28 ± 15 d prior to calving and ceased at 56 DIM. Values represent 
LS means for the Con, Med, and High Availa®Zn supplementation.  
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Figure 3.16:  Temporal pattern of plasma glucose concentration by parity (A) and 
treatment (B) from cows supplemented with organic zinc (OZ).  Control (Con) fed 
cows received no OZ supplementation, Medium (Med) cows were supplemented 
15.5 mg/kg of DM with Availa®Zn post-partum and High (High) cows were 
supplemented 40 mg/kg/ of DM with Availa®Zn post-partum. Treatment initiation 
occurred 28 ± 15 d prior to calving and ceased at 56 DIM. Values represent LS 
means for the Con, Med, and High Availa®Zn supplementation.  
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Figure 3.17:  Temporal pattern of plasma NEFA concentration by parity (A) and 
treatment (B) from cows supplemented with organic zinc (OZ).  Control (Con) fed 
cows received no OZ supplementation, Medium (Med) cows were supplemented 
15.5 mg/kg of DM with Availa®Zn post-partum and High (High) cows were 
supplemented 40 mg/kg/ of DM with Availa®Zn post-partum. Treatment initiation 
occurred 28 ± 15 d prior to calving and ceased at 56 DIM. Values represent LS 
means for the Con, Med, and High Availa®Zn supplementation.  
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Figure 3.18:  Temporal pattern of plasma BHBA concentration by parity (A) and 
treatment (B) from cows supplemented with organic zinc (OZ).  Control (Con) fed 
cows received no OZ supplementation, Medium (Med) cows were supplemented 
15.5 mg/kg of DM with Availa®Zn post-partum and High (High) cows were 
supplemented 40 mg/kg/ of DM with Availa®Zn post-partum. Treatment initiation 
occurred 28 ± 15 d prior to calving and ceased at 56 DIM. Values represent LS 
means for the Con, Med, and High Availa®Zn supplementation.  
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Figure 3.19:  Temporal pattern of rectal temperature by parity (A) and treatment (B) 
from cows supplemented with organic zinc (OZ).  Control (Con) fed cows received 
no OZ supplementation, Medium (Med) cows were supplemented 15.5 mg/kg of DM 
with Availa®Zn post-partum and High (High) cows were supplemented 40 mg/kg/ of 
DM with Availa®Zn post-partum. Treatment initiation occurred 28 ± 15 d prior to 
calving and ceased at 56 DIM. Values represent LS means for the Con, Med, and 
High Availa®Zn supplementation.  
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Figure 3.20:  Effect of treatment on health incidence frequency from cows 
supplemented with organic zinc (OZ).  Control (Con) fed cows received no OZ 
supplementation, Medium (Med) cows were supplemented 15.5 mg/kg of DM with 
Availa®Zn post-partum and High (High) cows were supplemented 40 mg/kg/ of DM 
with Availa®Zn post-partum. Treatment initiation occurred 28 ± 15 d prior to calving 
and ceased at 56 DIM. Values represent LS means for the Con, Med, and High 
Availa®Zn supplementation. 
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Figure 3.21:  Temporal pattern of endogenous plasma LPSBP x Days in Milk (A) 
and the effect of treatment (B) respectively from cows that either transitioned “well” 
or “poorly” into lactation. Values represent LS means (n=7 and 9, respectively) for 
the good and poor transition cows.  
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CHAPTER 4 
IMPLICATIONS 
 During the periparturient period the dairy cow must undergo a series of well-
orchestrated transitions through physiological states mediated by several substantial 
and coordinated metabolic adaptations to meet the demands for galactopoesis and 
ultimately copious production.  Physical capacity for feed intake is inadequate to 
meet the necessary demands for milk production and this consequently results in 
NEBAL. To date, NEBAL cannot be entirely overcome via dietary strategies.  Due to 
the energetic deficiency, cows will catabolize body protein and lipid stores.  
However, excessive loss of BCS in the early post-partum period is associated with 
reduced immune function, increased risk of metabolic disorders, and a reduction in 
subsequent reproductive performance.  Combining incidence rates for common 
transition period health problems (dystocia, metritis, ketosis, fatty liver, etc.), 
indicates approximately 50% of all cows experience at least one of these disorders 
during the periparturient period.  The objective of this thesis was to evaluate two 
dietary strategies and their respective ability to mitigate the effects of NEBAL and 
improve transition period success.   
 In the study described in Chapter 2 we sought to determine the effects of a 
protected (lipid-encapsulated) trans-10, cis-12 CLA isomer on milk production, 
health, culling frequency and reproduction in a large commercial dairy application.  
Previous research conducted in our group, has demonstrated that feeding CLA 
during the transition period may improve bio-energetic parameters such as EBAL, 
milk yield, and potentially reproduction.  More specifically our research has shown 
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EBAL nadir can be decreased by nearly five days (Moore et al., 2004).  The DIM at 
nadir is important for reproduction, as recovery of EBAL from its nadir provides an 
important signal for initiating ovarian activity (Lucy et al., 1992; Beam and Butler, 
1999) and days to NEBAL nadir are highly correlated with days to first ovulation 
(Butler, 2001).   
 Currently, CLA is a commercially available feed additive in Europe and 
Canada.  However, to be a commercially feasible product in US dairy systems, CLA 
must generate adequate MFD within short a period of time (14-28 d after parturition) 
and result in improved energetically dependent variables such as production, 
reproduction, and health or culling parameters.  We demonstrated the MFD 
generated by feeding CLA during the periparturient period to be insufficient to 
improve energetically dependent parameters.  No increase was observed in early 
lactation milk yield or components.  Further, no improvement was observed in long-
term (200 DIM) production variables or health events.  This experiment, the first 
commercial field trial in the US, failed to generate beneficial response, however this 
does not conclusively demonstrate that CLA is not an ineffective dietary strategy to 
improve EBAL.  To the contrary, the beneficial effects of CLA on lactational 
performance have been documented extensively in the literature, which have been 
previously addressed within this thesis.  The key finding from this study was that a 
controlled MFD resulting in improved calculated energetic status (via reduction in 
milk fat) is possible in a commercial setting, and based on the literature it is likely 
that increasing the CLA dose will improve to production variables. 
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The second study (Chapter 3) was conducted to assess the effects of 
increasing OZ supplementation on transition period production parameters.  
Negative energy balance is associated with (and maybe the cause of) the poor 
immune system status of the transition cow (Goff, 2006). Trace minerals, specifically 
Zn, play key roles in immune function (Miller et al., 1988).  The degree to which Zn 
status is believed to effect lactational performance has increased in accordance with 
our understanding of its biological role.  Organic chelation of minerals to amino acid 
complexes has been demonstrated to improve bioavailability (Wedekind et al., 
1992).   In a meta-analysis of twenty-two studies, OTM had a positive response on 
production parameters including milk production and components (Rabiee et al., 
2010).  However, results indicating the extent to which OZ effects production, and if 
a combination of inorganic and organic trace minerals would prove advantageous in 
early lactation are both respectively inconsistent.   
The results from our study did not demonstrate improvements in milk 
production, DMI, feed efficiency, metabolites or health events.  Commonly, in 
lactation Zn research, a reduction in SCC is observed, which could indicate 
improved immune system function, and possibly an improved EBAL status.  
However, a vast majority of these studies were conducted utilizing entirely OZ, not a 
mixture of inorganic and organic.  Conversely, we did not observe an improvement 
in SCCLN. However, we observed an increased colostrum IgG concentration in OZ 
supplemented multiparous cows.  Further research is necessary to better determine 
immune system status of OZ supplemented cows.  Also it would be of interest to 
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correlate transition period responses to OZ supplementation and established 
lactation performance.  
A key finding of this study was the retrospective observation of increased 
temporal LPSBP pattern in transition cows affected by metabolic disorders.  Our 
group’s documentation of endogenous LPSBP levels and its association with 
metabolic disorders is the first among published literature.    
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Appendix 
EFFECT OF IODINE SOURCE AND DOSE IN LACTATING HOLSTEIN COWS 
ABSTRACT 
Forty-eight lactating Holstein cows (3.25 ± 1.21 parity, 133 ± 47 DIM, 670 ± 
56 kg BW, 45.2 ± 8.4 kg milk yield) were housed at the Iowa State University Dairy 
Farm; and all procedures were reviewed and approved by the Iowa State University 
Institutional Animal Care and Use Committee.  All cows were fed a TMR ration 
delivered twice daily at 0800 and 1600h.  Ration formulation was by Dairy Health 
Services (Sanborn, IA) to meet or exceed predicted requirements (NRC, 2001) for 
energy, protein, minerals and vitamins.  Cows were selected and moved to a 
common pen (48 head capacity) 10 days prior to experiment initiation. Cows were 
assigned to 1 of 7 possible treatments based upon parity, days in milk (DIM) and 
milk yield.  Iodine products were weighed (to 0.1 mg accuracy) and inserted into size 
11 (10 mL) porcine gelatin capsules (Torpac Inc.  Fairfield, NJ).  All capsules were 
orally administered (by bolus) daily to all cows for 14 consecutive days.  Cows 
assigned to the control treatment received a capsule containing neither product.  
Bolusing occurred while cows were “locked-up” immediately after cows returned to 
the pen after the AM milking. Cows were observed for 5 min following bolusing to 
ensure against regurgitation. Milk samples from each cow (from both the AM and 
PM milking) were collected on d -2, -1, 3, 7, 10, 14, 17, 21, 24 and 28 relative to 
treatment initiation. One sample from each collection was stored at 4°C with a 
preservative (bronopol tablet; D&F Control System, San Ramon, CA) until analysis 
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by Dairy Lab Services (Dubuque IA) using AOAC approved infrared analysis 
equipment and procedures for milk components.  Blood samples were obtained via 
coccygeal venipuncture on d – 3, -1, 3, 7, 10, 14, 17, 21, 24 and 28 relative to 
treatment initiation using vacutainers designed for trace element testing (BD 
Vacutainer Ref 368380; Franklin Lakes, NJ).  Serum was harvested following 
centrifugation at 1500 x g for 15 minutes and subsequently frozen at -20°C until 
analysis.  Serum samples were analyzed for serum iodine concentration at Michigan 
State University’s Diagnostic Center for Population & Animal Health (Lansing, MI).  
Effects of treatment (1 to 7) and day (-4 or 28) and their interactions were assessed 
as a completely randomized design using PROC MIXED (SAS Inst. Inc., Cary, NC).  
A repeated measures analysis with an autoregressive covariance structure and day 
as the repeated effect was used to determine the effects of treatment, day and their 
interaction on repeated measurements (i.e. milk and serum iodine levels, milk yield 
etc.).  Production data and iodine levels (milk and serum) from d 7 to 14 (2nd week of 
supplementation) were combined for each cow and statistically analyzed using the 
PROC MIXED procedure of SAS (Tables A-1.1 and A-1.2).  All statistically analyzed 
data were covariately adjusted using their respective pre-supplementation (d -4 to -
1) values.  Results were reported as least squares means and considered to be 
significantly different when P ≤ 0.05.  
Experimental Design 
Cows were selected and moved to a common pen (48 head capacity) 10 days prior 
to experiment initiation. Cows were assigned to 1 of 7 possible treatments based 
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upon parity, days in milk (DIM) and milk yield. A cow from A30 was removed from 
the trial because of mastitis.  Treatment classification and animal distribution within 
treatments is as follows:  
 
Treatments: 1) Control, 0 mg supplemental iodine  /d  n = 6 
2) EDDI, 30 mg supplemental iodine  /d  n = 6 (A) 
3) EDDI, 60 mg supplemental iodine  /d  n = 7 (A) 
4) EDDI, 90 mg supplemental iodine  /d  n = 7 (A) 
5) Test product, 30 mg supplemental iodine  /d n = 7 (B) 
6) Test product, 60 mg supplemental iodine  /d n = 7 (B) 
7) Test product, 90 mg supplemental iodine  /d n = 7 (B) 
 
Figure A-1.1:  Experimental design schematic 
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Milk and Blood Sampling 
Both serum and milk iodine values for the 2nd week (average of d 7, 10 and 
14) are presented in Table A-1.1.  The smallest A dose (30 mg) did not increase (P > 
0.05) serum iodine levels (compared to control) but B30 dose increased (P < 0.05) 
serum iodine 69% (compared to controls).  Serum iodine levels did not differ 
amongst the lowest A or B dose (P > 0.05).  Compared to controls and A30, A60 
increased (P > 0.05) serum iodine by 106 and 50% respectively and there were no 
differences between A60 and B60 (Table A-1.2).  Interestingly, B30 was statistically 
similar (P > 0.05) to both A60 and B60. Both A90 and B 90 had a similar > 2 fold 
greater serum iodine concentration than controls and both had a 23% increased 
compared to A60 and B60.  There were no differences (P > 0.05) between the time 
point when (d 10) each dose reach maximum serum levels (Table A-1.2).  Maximum 
serum iodine levels mirrored that of the 2nd week average (Table A1.2). 
 The temporal patterns of serum iodine concentrations are graphically shown 
in Figures A-1.2 and A-1.3 and the AUC for each day of blood collection during the 
supplementation period is reported in Table 2.  The serum AUC data was similar to 
the 2nd week average, indicating that B30 (although not different than A30; P > 0.05) 
was similar to A60 and B60.  By d 14, both A90 and B90 serum iodine levels were 
larger (37%; P < 0.05) than the A60 and B60 doses. In every measure, within every 
dose and within every day, product B always had a numerically higher serum iodine 
level compared to product A (A-1.1). 
Serum Iodine Concentrations 
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In general, the differences between product, dose, day and temporal pattern were 
similar in milk iodine concentrations compared to serum iodine levels (Table A-1.1; 
Figures A-1.4, A-1.5 and A-1.6). Maximum milk iodine levels occurred on d 8 of 
supplementation but there were no differences amongst product or dose (P > 0.05; 
Table A-1.1).  The increase above control levels during the 2nd week of 
supplementation for the 30, 60 and 90 mg dose (independent of product) averaged 
62, 157 and 293%, respectively (much higher than observed in the serum iodine 
concentrations; Table A-1.1). 
Milk Iodine Concentrations 
  The relationship between serum iodine concentrations and milk iodine levels 
for all days and all products by dose combinations is shown in Figure A-1.7. The 
specific relationships between serum iodine levels and milk iodine concentrations 
amongst product A and product B just during the supplementation period is 
demonstrated in Figures A-1.8 through A-1.10.  
Production Parameters 
No treatment differences in any production parameter measured were 
detected (Table A-1.1, Figures A-1.11 to A-1.16).  There was no treatment effect on 
milk SCC (Table A-1.1) or SCS (Figure A-1.17), nor was there a relationship 
between milk iodine levels and SCS (Figure A-1.17).  
Conclusions 
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Both product A (EDDI) and product B (Zinpro test product) increased serum 
and milk iodine concentrations to a similar extent.  Although frequently not 
significant, the effects with product B (on both serum and milk) were consistently 
numerically higher than product A. Neither product had an effect on milk production 
parameters or somatic cell variables, but the project contained too few animals to 
make meaningful conclusions on production data. 
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Table A-1.1: Effects of increasing supplemental dietary iodine products (A and B) on production parameters and milk and serum 
iodine concentrations 
 Treatment   
Variable Con A30 B30 A60 B60 A90 B90 SEM P 
Milk Yield, kg/d 43.17 45.46 44.49 44.32 43.86 43.53 45.02 0.84 0.53 
Fat, % 3.45 3.38 3.50 3.43 3.49 3.40 3.41 0.13 0.99 
Protein, % 2.91 2.93 2.93 2.95 2.90 2.90 2.89 0.03 0.74 
Lactose, % 4.80 4.76 4.79 4.78 4.79 4.77 4.79 0.03 0.98 
Total Solids, % 12.03 11.96 12.09 12.10 12.09 11.99 12.00 0.12 0.98 
MUNa, mg/dL 12.4 12.9 13.7 13.4 11.9 12.2 12.7 0.5 0.10 
SCCb 56 288 131 182 182 261 127 84 0.53 
Ln SCSc 1.69 1.87 1.92 1.95 1.84 2.00 1.78 0.11 0.50 
Milk Iodine, µg/L 376a 561ab 664b 947c 983c 1113cd 1246d 74 <0.01 
Serum Iodine, ng/mL 78a 107ab 132bc 161c 161c 197d 200d 13 <0.01 
Data are from days 7 through 14 of supplemental period 
aMilk urea nitrogen 
bMilk somatic cell count 
cMilk somatic cell score 
abcdIndicates P < 0.05 
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Table A-1.2: Effects of increasing supplemental dietary iodine products (A and B) on milk and serum 
iodine concentration parameters. 
 Treatment   
Variable Con A30 B30 A60 B60 A90 B90 SE P 
Milk AUCa, mu g x L x d          
   day 3 . 441a 464a 835b 1071bc 1106bc 1247c 93 <0.01 
   day 7 . 1900a 2047a 3294b 4295c 4208cb 4896c 295 <0.01 
   day 10 . 3119a 3544a 5435b 6798c 6742c 7909c 475 <0.01 
   day 14 . 4422a 5301a 8286b 9788b 10279b 11990 732 <0.01 
Serum AUC, ng  x mL x d          
   day 3 . 39a 46a 71ab 79ab 131bc 162c 21 <0.01 
   day 7 . 170a 219ab 314ab 355b 511c 602c 54 <0.01 
   day 10 . 286a 384ab 543ab 615bc 831c 949c 85 <0.01 
   day 14 . 707a 909ab 1200bc 1252bc 1610d 1745d 130 <0.01 
          
Day of maximum milk I . 8.2 8.7 10.7 7.7 10.7 9.9 1.3 0.44 
Day of maximum serum I . 8.3 9.5 12.9 10.6 10.2 9.0 1.2 0.16 
          
Maximum milk I, µg/L . 689a 814a 1012ab 1238b 1225b 1381b 84 <0.01 
Maximum serum I, ng/mL . 118a 145ab 178bc 175bc 215cd 240d 17 <0.01 
aArea under the curve 
abcdIndicates P < 0.05 
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Figure A-1.2: Effects of increasing dose of dietary iodine (products A and 
B) on serum iodine concentrations in lactating Holstein cows. The 
supplement period is identified by vertical dashed lines. 
Figure A-1.3: Effects of increasing dose of dietary iodine (product A) on serum 
iodine concentrations in lactating Holstein cows. The supplement period is 
identified by vertical dashed lines. 
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Figure A-1.4: Effects of increasing dose of dietary iodine (product B) on serum 
iodine concentrations in lactating Holstein cows. The supplement period is 
identified by vertical dashed lines. 
Figure A-1.5: Effects of increasing dose of dietary iodine (products A and B) on 
milk iodine concentrations in lactating Holstein cows. The supplement period 
is identified by vertical dashed lines. 
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Figure A-1.6: Effects of increasing dose of dietary iodine (product A) on milk 
iodine concentrations in lactating Holstein cows. The supplement period is 
identified by vertical dashed lines. 
Figure A-1.7: Effects of increasing dose of dietary iodine (product B) on milk 
iodine concentrations in lactating Holstein cows. The supplement period is 
identified by vertical dashed lines. 
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Figure A-1.8:  Relationship between serum iodine concentrations and milk 
iodine levels in lactating Holstein cows. Data represent all sampled days and 
all cows within the data set. 
Figure A-1.9: Relationship between serum iodine concentrations and milk iodine 
levels in lactating Holstein cows.  Data represent sampled days from supplementation 
period from cows from Treatment A.  
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 Figure A-1.11: Effects of increasing dose of dietary iodine (products A and B) 
on milk yield in lactating Holstein cows. The supplement period is identified 
by vertical dashed lines. 
Figure A-1.10: Relationship between serum iodine concentrations and milk iodine 
levels in lactating Holstein cows.  Data represent sampled days from supplementation 
period from cows from Treatment B.  
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Figure A-1.12: Effects of increasing dose of dietary iodine (products A and B) 
on milk fat content in lactating Holstein cows. The supplement period is 
identified by vertical dashed lines. 
Figure A-1.13: Effects of increasing dose of dietary iodine (products A and B) 
on milk protein content in lactating Holstein cows. The supplement period is 
identified by vertical dashed lines. 
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Figure A-1.14: Effects of increasing dose of dietary iodine (products A and B) 
on milk fat lactose content in lactating Holstein cows. The supplement period 
is identified by vertical dashed lines. 
Figure A-1.15: Effects of increasing dose of dietary iodine (products A and B) on 
milk somatic cell score in lactating Holstein cows. The supplement period is 
identified by vertical dashed lines. 
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Figure A-1.16: Effects of increasing dose of dietary iodine (products A and B) 
on milk urea nitrogen in lactating Holstein cows. The supplement period is 
identified by vertical dashed lines. 
Figure A-1.17: Relationship between milk iodine concentrations and milk somatic cell 
score in lactating Holstein cows.  Data represent sampled days from supplementation 
period from cows from treatment A and B.  
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Table A-1.3:  Effect of CLA supplementation on plasma metabolites and mineral concentrations.  
 Treatment    P  
Parameter  Con Med High    SEM  TRT DIM    TRT x DIM    Contrast 
Glucose, mg/dL 62.8a 55.1b 57.1b 1.8 0.01 <0.01 0.41 <0.01 
Albumin, g/dL 3.0 2.9 3.1 0.08 0.09 0.04 0.53 0.57 
BUN1, mg/dL 8.0 8.8 10.6 0.04 <0.01 <0.01 0.89 0.01 
Calcium, mg/dL 10.1 9.8 10.3 0.2 0.37 0.02 0.35 0.66 
Creatine 0.8 0.8 0.8 0.03 0.53 <0.01 <0.01 0.65 
GGT2 27.5 26.5 33.5 4.7 0.55 0.02 0.96 0.70 
BHBA3, mg/dL  6.7 8.0 7.7 0.6 0.31 <0.01 0.76 0.13 
Magnesium, mg/dL 2.1 2.0 2.1 0.05 0.75 <0.01 0.41 0.87 
Phosphorus, mg/dL 6.0 6.1 6.5 0.1 0.16 0.01 0.29 0.30 
Total Protein, g/dL 6.6a 6.4a 7.1b 0.1 0.02 0.01 0.90 0.55 
1Blood Urea Nitrogen 
2Gamma-glutamyl Transferase 
3 β-hydroxybutyrtic acid 
abIndicates P < 0.05   
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